U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                   FORM 10-KSB

(Mark One)

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
                               For the fiscal year ended March 31, 2006.


TRANSITION  REPORT UNDER SECTION 13 OR 15(d) OF THE  SECURITIES  EXCHANGE ACT OF
1934
                               For the transition period from _______ to _______


                         Commission file number: 0-30520


                        GLOBAL IMMUNE TECHNOLOGIES, INC.
                 (Name of Small Business Issuer in its Charter)


         Wyoming
------------------------                         -------------------------------
(State of Incorporation)                         (IRSEmployerIdentification No.)



1518 West Hastings St., Vancouver, B.C. Canada                V6G 3J4
----------------------------------------------       ---------------------------
   (Address of principal executive offices)                  (Zip Code)



Issuer's telephone number, (   604   )      351      -      9443
                           -----------  ------------   --------------

        Securities Registered Pursuant of Section 12(b) of the Act: None

           Securities Registered Pursuant of Section 12(g) of the Act:
                         Common Stock, Without Par Value

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Securities  Exchange  Act of 1934  during the  preceding  12
months (or for such shorter period that the registrant was required to file such
reports),  and (2) has been subject to such filing  requirements for the past 90
days. Yes [X] No [ ]

Check if there is no disclosure of delinquent  filers in response to Item 405 of
Regulation S-B in this form, and no disclosure will be contained, to the best of
registrant's   knowledge,   in  definitive   proxy  or  information   statements
incorporated  by reference  in Part III of this Form 10-KSB or any  amendment of
this Form 10-KSB. [ ]

Indicate by check mark whether the  registrant is a shell company (as defined by
Rule 12b-2 of the Exchange Act). Yes X  No
                                    ---   ---

The issuer had operating revenues of $-0- for the year ended March 31, 2006.

As of March 31, 2006, there were 116,195,645 shares of the issuer's common stock
outstanding.  The  aggregate  market value of the shares of the issuer's  voting
stock held by  non-affiliates  was  $2,591,303  based the average of the bid and
asked price as quoted on the OTC  Electronic  Bulletin  Board on March 31, 2006.
The sum excludes the shares held by officers,  directors, and stockholders whose
ownership exceeded 10% of the outstanding shares at March 31, 2006, in that such
persons may be deemed affiliates of the Company. This determination of affiliate
status is not necessarily a conclusive determination for other purposes.


<PAGE>


                        Global Immune Technologies, Inc.
                                   FORM 10-KSB
                                 March 31, 2006


                                                                            Page
PART I......................................................................   2

ITEM 1.  Description of Business............................................   2
ITEM 2.  Description of Properties..........................................  13
ITEM 3.  Legal Proceedings..................................................  13
ITEM 4.  Submission of Matters to Vote of Security Holders..................  13

PART II.....................................................................  14

ITEM 5.  Market for Common Equity, Related Stockholder Matters and Small
           Business Issuer Purchases of Equity Securities...................  14
ITEM 6.  Management's Discussion and Analysis or Plan of Operation..........  15
ITEM 7.  Financial Statements...............................................  17
ITEM 8.  Changes In and Disagreements With Accounting and Financial
           Disclosure.......................................................  17
ITEM 8A. Controls and Procedures............................................  18
ITEM 8B. Other Information..................................................  19

PART III....................................................................  20

ITEM 9.  Directors, Executive Officers, Promoters, and Control
           Persons: Compliance with Section 16(a) of the Exchange Act.......  20
ITEM 10. Executive Compensation.............................................  21
ITEM 11. Security Ownership of Certain Beneficial Owners and Management and
           Related Stockholder Matters......................................  22
ITEM 12. Certain Relationships and Related Transactions.....................  23
ITEM 13. Exhibits...........................................................  24
ITEM 14. Principal Accounting Fees and Services.............................  24
SIGNATURES..................................................................  24







                                       1
<PAGE>

PART I

Item 1.    Description of Business.

FORWARD-LOOKING STATEMENT NOTICE:

This annual  report on Form 10-KSB  contains  many  forward-looking  statements,
which  involve  risks  and   uncertainties,   such  as  our  plans,   objective,
expectations  and  intentions.  You can identify these  statements by our use of
words  such as "may,"  "expect,"  "believe,"  "anticipate,"  "intend,"  "could,"
"estimate,"  "continue,"  "plans," or other  similar  words or phrases.  Some of
these statements include discussions  regarding our future business strategy and
our ability to generate revenue,  income,  and cash flow. We wish to caution the
reader that all  forward-looking  statements  contained  in this Form 10-KSB are
only estimates and predictions.  Our actual results could differ materially from
those  anticipated as a result of risk facing us or actual events differing from
the  assumptions  underlying  such  forward-looking   statements.   Readers  are
cautioned  not  to  place  undue  reliance  on  any  forward-looking  statements
contained in this Annual  Report on Form 10-KSB.  Readers are  cautioned  not to
place undue  reliance  on these  forward-looking  statements.  We  undertake  no
obligation to update any of these factors or to publicly  announce any change to
our  forward-looking  statements  made  herein,  whether  as  a  result  of  new
information, future events, changes in expectations or otherwise.


         (a) Our Corporate History.
             ---------------------

The  Company was  incorporated  on  September  18,  1985,  under the laws of the
Province of British  Columbia  under the name of Canadian  Comstock  Exploration
Ltd. with an authorized share capital of 20,000,000 shares without par value.

The Company  changed its name on June 7, 1995 to American  Comstock  Exploration
Ltd. in connection with a  consolidation  of its share capital on a one for four
basis.

The  Company  changed  its name  again on  February  4,  1998 to  "International
Comstock  Exploration  Ltd." in  connection  with a  consolidation  of its share
capital on a one for five basis.

The  Company  changed its name again on October 2, 2001 to  "Secureview  Systems
Inc." in connection with a consolidation  of its share capital on a one for five
basis.  In addition,  the Company  increased  its  authorized  share  capital to
100,000,000 shares without par value on October 2, 2001.

The Company changed its name again on May 2, 2005 to "Global Immune Technologies
Inc." In addition,  the Company  increased  its  authorized  share capital to an
unlimited number of common shares without par value on March 23, 2005.

On February 28, 2006,  the Company  changed its corporate  domicile from British
Columbia, Canada to the State of Wyoming.

         (b) Business History of the Issuer.
             ------------------------------

From its  incorporation  in 1985 until 1999, the Company has been engaged in the
business of exploration of natural resource properties.  During 2004 the Company
disposed of its final  interests in its natural  resource  properties.  In early
1999 the Company initiated a search for other business opportunities culminating
in May 1999  with the  acquisition  of the  domain  name  ProSportsPool.com.  In
January 2000, the Company entered into an agreement with Internet Sports Network
Inc. to develop  and  maintain a number of  internet  based games and  contests.
Internet Sports Network eventually developed "Fantasy Free for All" software and
back end support for Nascar,  Formula  One,  Cart series and Baseball and Hockey
contests  for  ProSportsPool.com.  The  Company  launched  the  ProSportsool.com
website on March 1, 2000 with Formula 1 and NASCAR  contests  "Fantasy  Free for
All".  The launch of the website was  accompanied  by a marketing  campaign that
included print, billboard, and internet-banner  advertising.  In March 21, 2000,
the Company  engaged  Iceberg  Media.com  Inc. to provide three music channels -
1Groove.com,  2Kool4Radio.com  and  PrimeTicket.net - for the  ProSportsPool.com
website. The ProSportsPool.com  website added a fantasy baseball contest, and an
affiliation  with  Altavista.com  on March 27, 2000.  At the  beginning of April
2000,  the Company  launched its internet based hockey contest and announced its
inaugural  contest  winners  in  its  auto-racing  contests.  The  Company  also
announced it has become an authorized  member of the Cnet.com  affiliate network
and formed similar affiliations with Chipshot.com, Wrenchead.com, Quokka.com and
America Online.



                                       2
<PAGE>

To increase awareness of the ProSportspool.com website, the Company participated
at the G.I.  Joe 200 CART race in  Portland,  Oregon as well as the  Toronto and
Vancouver Indy races by appearing at a booth at the races signing up contestants
and  offering  prizes to entrants.  On January 15,  2001,  due to the closing of
Internet  Sports  Network Inc.,  which provided the technical  architecture  and
sports data for the ProSportsPool.com's  sports contests, the Company was forced
to discontinue its sports-contest site.

During June 2001 and amended October,  2001 the Company entered into a letter of
intent with Argent Resources Ltd.,  On-Track  Computer  Training Ltd.,  On-Track
Computer International Ltd. and Lute Linux.com Corp. whereby Argent assigned its
right to enter into a share exchange  agreement with Lute who held the option to
enter into a share exchange agreement with On-Track and On-Track  International.
In exchange for the  assignment  by Argent to the Company of the share  exchange
agreement  entered into between Lute and Argent,  the Company  issued  2,000,000
shares and paid $50,000 to Argent.

During October 2001 the Company  signed an agreement  with Lute Linux.com  Corp.
including the exchange of Lute share  purchase  warrants for Company shares at a
deemed  value of $0.10 US per share,  as to Russ Rossi  (100,000  shares),  RRGS
Creative  Management Corp.  (2,400,000  shares) and Quest Ventures Ltd. (175,000
shares). The Company did not proceed with similar share purchase agreements with
On-Track Computer Training Ltd. and On-Track  Computer  International  Ltd. Lute
focused  its  business  development  on  its  "Fedcam,"  an  inexpensive  remote
monitoring  system that allows  subscribers  to view their target  locations via
secure  website.  The  Fedcam  was  being  tested by the  Canadian  government's
construction  branch on its Osoyoos,  British Columbia border crossing site into
the United States. However, as of March 31, 2003, the Company ceased funding the
Fedcam and the asset was written down to a nominal amount.

In June 2002 the Company entered into a letter of intent with Estwind Energy,  a
private power generation  company  incorporated in Estonia,  whereby the Company
intended to acquire all of the issued and outstanding  shares of Estwind Energy.
However,  the Company decided against completing the share exchange agreement as
the business of Estwind Energy was deemed to not be profitable.

In May 2003 the Company  entered  into a letter of intent  with P-CE  Computers,
Inc.,  a private  Nevada  corporation  engaged  in the  business  of  developing
ergonomic   multimedia-computer   workstations.   The  Company  decided  against
completing  the share  exchange  agreement as due diligence  indicated  that the
business of P-CE Computers, Inc. would not be profitable.

In September 2003 the Company entered into a letter of intent with TNR Resources
Ltd. ("TNR"), a public British Columbia, Canada,  corporation, to purchase a 50%
working  interest in TNR's Las Carachas  property in Argentina.  The Company did
not pursue the option.

In February  2005 the  Company  entered an  agreement  to acquire the rights and
interests  in a drug,  Trioxolane.  The Company did not pursue or complete  this
acquisition.

Subsequently  to March 31, 2005,  the Company has agreed to purchase WSG Systems
Inc.,  ("WSG") its' business and assets from Global Lottery  Corporation for the
issuance  of  100,000,000  shares of common  stock.  The  assets of WSG  include
proprietary  technology,  software,  its  trade  names and  trademarks  as those
products pertain to the worldwide lottery industry and/or worldwide  pari-mutual
betting.  The  products  are designed to be used by all entities in the industry
for conducting  lotteries and or  pari-mutual  betting,  including  corporations
and/or governmental agencies representing countries,  provinces, states, etc. to
implement and/or to improve their lottery and/or pari-mutual betting systems.

On July 19, 2006, the Company entered into a securities  exchange agreement with
MediPri Limited, Primemedical International, Ltd.("MedPri") and Medical Monitors
Limited  ("MML).  The  transaction  is pending  subject  to various  performance
obligations of the parties.

         (c) Current Business of the Issuer
             ------------------------------

The Company may be referred to as a shell  corporation.  Shell  corporations are
defined as companies with no or nominal assets and operations. Private companies
wishing  to become  publicly  trading  may wish to merge with a shell (a reverse
merger)  whereby the  shareholders of the private Company become the majority of
the shareholders of the combined  Company.  The private Company may purchase for
cash all or a portion of the  common  shares of the shell  corporation  from its
major  stockholders.  Typically,  the Board and officers of the private  Company
become the new Board and officers of the combined  Company and often the name of
the private Company becomes the name of the combined Company.


                                       3
<PAGE>

The Company has very limited  capital,  and it is unlikely that the Company will
be able to take  advantage  of more  than one  such  business  opportunity.  The
Company intends to seek  opportunities  demonstrating the potential of long-term
growth as opposed to short-term  earnings.  However,  at the present  time,  the
Company has not identified any business opportunity that it plans to pursue, nor
has the Company  reached any  agreement  or  definitive  understanding  with any
person concerning an acquisition.

No  assurance  can be given that the Company  will be  successful  in finding or
acquiring a desirable  business  opportunity,  given the limited  funds that are
expected to be available  for  acquisitions.  Furthermore,  no assurance  can be
given  that  any  acquisition,  which  does  occur,  will be on  terms  that are
favorable to the Company or its current stockholders.

The Company's search will be directed toward small and medium-sized enterprises,
which have a desire to become public corporations. In addition these enterprises
may wish to satisfy,  either  currently or in the  reasonably  near future,  the
minimum  tangible  asset  requirement  in order to qualify shares for trading on
NASDAQ or on an exchange such as the American Stock Exchange. (See Investigation
and  Selection  of Business  Opportunities).  The Company  anticipates  that the
business  opportunities  presented  to it will (i)  either be in the  process of
formation,  or be recently organized with limited operating history or a history
of  losses  attributable  to   under-capitalization   or  other  factors;   (ii)
experiencing financial or operating  difficulties;  (iii) be in need of funds to
develop new  products or services or to expand into a new market,  or have plans
for rapid expansion through acquisition of competing  businesses;  (iv) or other
similar  characteristics.  The Company  intends to concentrate  its  acquisition
efforts on properties or businesses  that it believes to be  undervalued or that
it believes may realize a substantial  benefit from being publicly owned.  Given
the above factors,  investors  should expect that any acquisition  candidate may
have  little  or  no  operating   history,   or  a  history  of  losses  or  low
profitability.

The Company does not propose to restrict its search for investment opportunities
to any particular  geographical area or industry, and may, therefore,  engage in
essentially any business, to the extent of its limited resources.  This includes
industries such as service,  finance,  natural  resources,  manufacturing,  high
technology,  product  development,   medical,  communications  and  others.  The
Company's discretion in the selection of business opportunities is unrestricted,
subject to the  availability of such  opportunities,  economic  conditions,  and
other factors.

In  connection  with such a merger or  acquisition,  it is highly likely that an
amount of stock  constituting  control of the Company  would either be issued by
the Company or be  purchased  from the  current  principal  stockholders  of the
Company by the acquiring  entity or its  affiliates.  If stock is purchased from
the  current  principal  stockholders,  the  transaction  is likely to result in
substantial  gains  to the  current  principal  stockholders  relative  to their
purchase price for such stock. In the Company's  judgment,  none of the officers
and directors  would  thereby  become an  underwriter  within the meaning of the
Section  2(11)  of the  Securities  Act of  1933,  as  amended  as  long  as the
transaction  is a  private  transaction  rather  than a public  distribution  of
securities. The sale of a controlling interest by certain principal shareholders
of the Company  would occur at a time when minority  stockholders  are unable to
sell their shares because of the lack of a public market for such shares.

Depending upon the nature of the transaction, the current officers and directors
of the Company may resign their  management and board positions with the Company
in connection with a change of control or acquisition of a business  opportunity
(See  Form of  Acquisition,  below,  and  Risk  Factors,  The  Company,  Lack of
Continuity of  Management).  In the event of such a  resignation,  the Company's
current  management  would  thereafter  have no control  over the conduct of the
Company's business.

It is  anticipated  that  business  opportunities  will  come  to the  Company's
attention from various sources,  including its officers and directors, its other
stockholders,   professional   advisors  such  as  attorneys  and   accountants,
securities  broker-dealers,   venture  capitalists,  members  of  the  financial
community,  and others who may present unsolicited proposals. The Company has no
plan,  understandings,  agreements,  or commitments with any individual for such
person to act as a finder of opportunities for the Company.

The  Company  does not foresee  that it will enter into a merger or  acquisition
transaction with any business with which its officers or directors are currently
affiliated. Should the Company determine in the future, contrary to the forgoing
expectations,  that a  transaction  with  an  affiliate  would  be in  the  best
interests  of the  Company  and its  stockholders,  the  Company is, in general,


                                       4
<PAGE>

permitted by Wyoming law to enter into a transaction  if: The material  facts as
to the  relationship  or interest  of the  affiliate  and as to the  contract or
transaction are disclosed or are known to the Board of Directors,  and the Board
in good faith  authorizes,  approves or ratifies the contract or  transaction by
the affirmative vote of a majority of the disinterested  directors,  even though
the disinterested directors constitute less than a quorum; or the material facts
as to the  relationship  or interest of the  affiliate and as to the contract or
transaction  are  disclosed  or are known to the  stockholders  entitled to vote
thereon, and the contract or transaction is specifically authorized, approved or
ratified  in  good  faith  by  vote  of the  stockholders;  or the  contract  or
transaction is fair as to the Company as of the time it is authorized,  approved
or ratified, by the Board of Directors or the stockholders.

         (1) Investigation and Selection of Business Opportunities

To a large extent, a decision to participate in a specific business  opportunity
may be made upon  management's  analysis of the  quality of the other  Company's
management  and  personnel,  the  anticipated  acceptability  of new products or
marketing concepts,  the merit of technological  changes,  the perceived benefit
the business  opportunity will derive from becoming a publicly held entity,  and
numerous  other  factors  which are  difficult,  if not  impossible,  to analyze
through the  application of any objective  criteria.  In many  instances,  it is
anticipated that the historical  operations of a specific  business  opportunity
may not  necessarily  be indicative of the potential for the future because of a
variety of factors,  including,  but not limited to, the possible need to expand
substantially,  shift marketing approaches,  change product emphasis,  change or
substantially augment management, raise capital and the like.

It is  anticipated  that the  Company  will not be able to  diversify,  but will
essentially be limited to the acquisition of one business opportunity because of
the Company's limited financing.  This lack of  diversification  will not permit
the Company to offset  potential  losses from one business  opportunity  against
profits from another,  and should be considered an adverse factor  affecting any
decision to purchase the Company's securities.

Certain types of business acquisition  transactions may be completed without any
requirement  that the Company first submit the  transaction to the  stockholders
for their approval.  In the event the proposed transaction is structured in such
a fashion that  stockholder  approval is not required,  holders of the Company's
securities (other than principal  stockholders  holding a controlling  interest)
should not anticipate  that they will be provided with  financial  statements or
any other documentation prior to the completion of the transaction.  Other types
of transactions require prior approval of the stockholders.

In the event a proposed business combination or business acquisition transaction
is  structured in such a fashion that prior  stockholder  approval is necessary,
the  Company  will be  required  to  prepare  a Proxy or  Information  Statement
describing  the proposed  transaction,  file it with the Securities and Exchange
Commission  for  review  and  approval,  and  mail a copy  of it to all  Company
stockholders  prior to holding a stockholders  meeting for purposes of voting on
the  proposal.  Minority  shareholders  that do not vote in favor of a  proposed
transaction may then have the right, in the event the transaction is approved by
the required number of stockholders,  to exercise  statutory  dissenter's rights
and elect to be paid the fair value of their shares.

The  analysis  of  business  opportunities  will be  undertaken  by or under the
supervision  of  the  Company's  officers  and  directors,   none  of  whom  are
professional  business analysts (See Management).  Although there are no current
plans to do so, Company management might hire an outside consultant to assist in
the  investigation  and  selection  of business  opportunities,  and might pay a
finder's fee.  Since Company  management has no current plans to use any outside
consultants or advisors to assist in the investigation and selection of business
opportunities,  no policies have been adopted  regarding use of such consultants
or advisors,  the criteria to be used in selecting such consultants or advisors,
the  services to be provided,  the term of service,  or the total amount of fees
that may be paid.  However,  because of the limited resources of the Company, it
is likely that any such fee the Company agrees to pay would be paid in stock and
not in cash.

Otherwise,  in analyzing  potential business  opportunities,  Company management
anticipates that it will consider, among other things, the following factors:

     o    Potential for growth and  profitability  indicated by new  technology,
          anticipated market expansion, or new products;

     o    The Company's  perception of how any particular  business  opportunity
          will be  received by the  investment  community  and by the  Company's
          stockholders;



                                       5
<PAGE>

     o    Whether,  following the business combination,  the financial condition
          of the  business  opportunity  would be, or would  have a  significant
          prospect in the foreseeable  future of becoming,  sufficient to enable
          the securities of the Company to qualify for listing on an exchange or
          on a national automated  securities  quotation system, such as NASDAQ,
          so as to permit the trading of such  securities  to be exempt from the
          requirements  of Rule 15g-9  adopted by the  Securities  and  Exchange
          Commission (See Risk Factors The Company Regulations of Penny Stocks).

     o    Capital  requirements and anticipated  availability of required funds,
          to be provided by the Company or from operations,  through the sale of
          additional securities, through joint ventures or similar arrangements,
          or from other sources;

     o    The extent to which the business opportunity can be advanced;

     o    Competitive  position as compared to other  companies  of similar size
          and  experience  within  the  industry  segment  as well as within the
          industry as a whole;

     o    Strength and diversity of existing management or management  prospects
          that are scheduled for recruitment;

     o    The cost of  participation by the Company as compared to the perceived
          tangible and intangible values and potential; and

     o    The accessibility of required  management  expertise,  personnel,  raw
          materials,  services,  professional  assistance,  and  other  required
          items.

No one of the factors  described above will be controlling in the selection of a
business  opportunity,  and  management  will  attempt  to analyze  all  factors
appropriate to each  opportunity and make a determination  based upon reasonable
investigative  measures  and  available  data.  Potentially  available  business
opportunities  may occur in many  different  industries and at various stages of
development,  all of which will make the task of comparative  investigation  and
analysis  of  such  business  opportunities  extremely  difficult  and  complex.
Potential  investors  must  recognize  that,  because of the  Company's  limited
capital  available for  investigation  and  management's  limited  experience in
business analysis,  the Company may not discover or adequately  evaluate adverse
facts about the opportunity to be acquired.

The  Company  is  unable  to  predict  when  it may  participate  in a  business
opportunity.  It expects,  however,  that the analysis of specific proposals and
the selection of a business opportunity may take several months or more.

Prior to making a decision to participate in a business opportunity, the Company
will generally request that it be provided with written materials  regarding the
business  opportunity  containing  as much  relevant  information  as  possible,
including, but not limited to, such items as a description of products, services
and  Company  history;  management  resumes;  financial  information;  available
projections,  with related assumptions upon which they are based; an explanation
of proprietary products and services; evidence of existing patents,  trademarks,
or service marks, or rights thereto;  present and proposed forms of compensation
to  management;  a  description  of  transactions  between  such Company and its
affiliates  during the relevant  periods;  a description of present and required
facilities;,  an analysis of risks and competitive conditions;  a financial plan
of operation and estimated capital  requirements;  audited financial statements,
or if they are not  available,  unaudited  financial  statements,  together with
reasonable  assurance  that  audited  financial  statements  would be able to be
produced  within a  reasonable  period of time not to  exceed 60 days  following
completion of a merger or acquisition transaction; and the like.

As part of the Company's  investigation,  the Company's  executive  officers and
directors may meet personally  with management and key personnel,  may visit and
inspect  material  facilities,  obtain  independent  analysis or verification of
certain information provided,  check references of management and key personnel,
and take other reasonable investigative measures, to the extent of the Company's
limited financial resources and management expertise.

It is possible that the range of business  opportunities that might be available
for  consideration  by the Company  could be limited by the impact of Securities
and Exchange Commission regulations regarding purchase and sale of penny stocks.
The regulations would affect, and possibly impair, any market that might develop
in the  Company's  securities  until such time as they  qualify  for  listing on
NASDAQ or on an exchange which would make them exempt from  applicability of the
penny stock regulations. (See Risk Factors Regulation of Penny Stocks)


                                       6
<PAGE>

Company   management   believes  that  various  types  of  potential  merger  or
acquisition  candidates might find a business combination with the Company to be
attractive.  These include  acquisition  candidates  desiring to create a public
market for their shares in order to enhance liquidity for current  stockholders,
acquisition  candidates  which have long-term  plans for raising capital through
public sale of  securities  and believe that the possible  prior  existence of a
public  market  for  their  securities  would  be  beneficial,  and  acquisition
candidates  which  plan  to  acquire   additional  assets  through  issuance  of
securities rather than for cash, and believe that the possibility of development
of a public market for their  securities  will be of assistance in that process.
Acquisition  candidates,  which have a need for an immediate cash infusion,  are
not likely to find a potential  business  combination  with the Company to be an
attractive alternative.

         (2) Form of Acquisition

It is impossible to predict the manner in which the Company may participate in a
business opportunity.  Specific business  opportunities will be reviewed as well
as the  respective  needs and desires of the Company  and the  promoters  of the
opportunity  and,  upon the basis of the  review  and the  relative  negotiating
strength of the Company and such promoters, the legal structure or method deemed
by management to be suitable will be selected.  Such structure may include,  but
is not limited to leases, purchase and sale agreements, licenses, joint ventures
and other contractual  arrangements.  The Company may act directly or indirectly
through an interest in a partnership, corporation or other form of organization.
Implementing   such   structure  may  require  the  merger,   consolidation   or
reorganization  of the  Company  with other  corporations  or forms of  business
organization.  In  addition,  the present  management  and  stockholders  of the
Company  most likely will not have  control of a majority of the voting stock of
the Company following a merger or reorganization  transaction. As part of such a
transaction,  the Company's  existing directors may resign and new directors may
be appointed without any vote by stockholders.

It is likely  that the Company  will  acquire  its  participation  in a business
opportunity  through the  issuance of Common  Stock or other  securities  of the
Company.  Although the terms of any such  transaction  cannot be  predicted,  it
should be noted that in  certain  circumstances  the  criteria  for  determining
whether or not an acquisition is a so-called B tax free reorganization under the
Internal  Revenue  Code of 1986 as  amended,  depends  upon the  issuance to the
stockholders of the acquired  Company of a controlling  interest  (i.e.,  80% or
more) of the common stock of the combined  entities  immediately  following  the
reorganization.  If a transaction  were  structured  to take  advantage of these
provisions  rather than other a tax free provisions  provided under the Internal
Revenue Code, the Company's current  stockholders  would retain in the aggregate
20% or less of the total  issued and  outstanding  shares.  This could result in
substantial  additional dilution in the equity of those who were stockholders of
the Company prior to such reorganization. Any such issuance of additional shares
might also be done simultaneously with a sale or transfer of shares representing
a  controlling  interest in the Company by the current  officers,  directors and
principal stockholders.

It is anticipated that any new securities issued in any reorganization  would be
issued  in  reliance  upon  one  or  more  exemptions  from  registration  under
applicable  federal and state securities laws to the extent that such exemptions
are available.  In some  circumstances,  however, as a negotiated element of the
transaction,  the Company may agree to register  such  securities  either at the
time the  transaction is  consummated  or under certain  conditions at specified
times thereafter.  The issuance of substantial  additional  securities and their
potential  sale into any  trading  market  that might  develop in the  Company's
securities may have a depressive effect upon such market.

The  Company  will  participate  in  a  business   opportunity  only  after  the
negotiation  and  execution of a written  agreement.  Although the terms of such
agreement  cannot  be  predicted,  generally  such an  agreement  would  require
specific  representations and warranties by all of the parties thereto,  specify
certain events of default,  detail the terms of closing and the conditions which
must be satisfied by each of the parties thereto prior to such closing,  outline
the manner of bearing costs if the transaction is not closed, set forth remedies
upon default, and include miscellaneous other terms.

As a general  matter,  the Company  anticipates  that it,  and/or its  principal
stockholders will enter into a letter of intent with the management,  principals
or owners  of a  prospective  business  opportunity  prior to  signing a binding
agreement.  Such a letter  of intent  will set  forth the terms of the  proposed
acquisition but will not bind any of the parties to consummate the  transaction.
Execution of a letter of intent will by no means indicate that  consummation  of


                                       7
<PAGE>

an acquisition is probable.  Neither the Company nor any of the other parties to
the letter of intent  will be bound to  consummate  the  acquisition  unless and
until a definitive  agreement is executed.  Even after a definitive agreement is
executed,  it is possible that the acquisition  would not be consummated  should
any party elect to exercise any right  provided in the agreement to terminate it
on specific grounds.

It is anticipated that the investigation of specific business  opportunities and
the  negotiation,  drafting  and  execution of relevant  agreements,  disclosure
documents and other  instruments  will require  substantial  management time and
attention and  substantial  costs for  accountants,  attorneys and others.  If a
decision is made not to  participate  in a specific  business  opportunity,  the
costs incurred in the related investigation would not be recoverable.  Moreover,
because many providers of goods and services require compensation at the time or
soon after the goods and services are provided,  the inability of the Company to
pay until an  indeterminate  future time may make it impossible to produce goods
and services.

         (3) Investment Company Act and Other Regulation

The Company may participate in a business opportunity by purchasing,  trading or
selling the securities of such business.  The Company does not, however,  intend
to engage  primarily in such  activities.  Specifically,  the Company intends to
conduct its activities so as to avoid being classified as an investment  Company
under the Investment  Company Act of 1940 (the Investment Act), and therefore to
avoid  application  of  the  costly  and  restrictive   registration  and  other
provisions of the Investment Act, and the regulations promulgated thereunder.

The  Company's  plan of business may involve  changes in its capital  structure,
management,   control  and   business,   especially   if  it   consummates   the
reorganization  as  discussed  above.  Each of these areas is  regulated  by the
Investment Act, in order to protect purchasers of investment Company securities.
Since the Company will not register as an investment Company,  stockholders will
not be afforded these protections.

Employees
---------

As of March 31, 2006 the Company had no full-time employees. Donald Perks is the
Company's sole officer and director. Mr. Perks works on a part-time basis.

RISK FACTORS

THERE ARE SIGNIFICANT  RISKS  ASSOCIATED WITH AN INVESTMENT IN OUR COMMON STOCK.
BEFORE MAKING A DECISION  CONCERNING THE PURCHASE OF OUR SECURITIES,  YOU SHOULD
CAREFULLY  CONSIDER THE FOLLOWING  FACTORS AND OTHER  INFORMATION IN THIS ANNUAL
REPORT WHEN YOU EVALUATE OUR BUSINESS.

BUSINESS RISKS

LACK OF BUSINESS HISTORY AND PROFITABILITY OF OPERATIONS
The Company is not currently  operating  profitably and it should be anticipated
that it will  operate at a loss at least until such time as a business  prospect
is identified and profitability is achieved,  if profitability is, in fact, ever
achieved. The Company has never earned a significant profit.

DEPENDENCE ON KEY MANAGEMENT
The success of the  operations  and  activities of the Company is dependent to a
significant  extent on the efforts and abilities of its management.  The loss of
services of any of its  Management  could have a material  adverse effect on the
Company.  The  Company  does  not  maintain  key  man  insurance  on  any of its
management.  The Company does not have any employment or labor  agreements  with
any personnel as at the date of the filing of this Annual Report.

CONFLICTS OF INTEREST.  Certain  conflicts of interest exist between the Company
and its officers and directors. They have other business interests to which they
currently devote attention,  and are expected to continue to do so. As a result,
conflicts of interest may arise that can be resolved only through their exercise
of judgment in a manner which is consistent with their  fiduciary  duties to the
Company.

It is  anticipated  that  the  Company's  principal  shareholders  may  actively
negotiate  or  otherwise  consent to the  purchase of a portion of their  common
stock as a condition to, or in connection with, a proposed merger or acquisition
transaction.  In this process, the Company's principal shareholders may consider



                                       8
<PAGE>

their own  personal  pecuniary  benefit  rather than the best  interest of other
Company  shareholders.  Depending  upon the  nature of a  proposed  transaction,
Company  shareholders other than the principal  shareholders may not be afforded
the opportunity to approve or consent to a particular transaction.

INVESTMENT RISKS

OUR ISSUANCE OF  ADDITIONAL  SHARES MAY HAVE THE EFFECT OF DILUTING THE INTEREST
OF SHAREHOLDERS; OUR COMMON STOCK SHAREHOLDERS DO NOT HAVE PREEMPTIVE RIGHTS.

Any additional  issuances of common stock by us from our authorized but unissued
shares may have the effect of  diluting  the  percentage  interest  of  existing
shareholders.  The securities issued to raise funds may have rights, preferences
or privileges  that are senior to those of the holders of our other  securities,
including our common  stock.  The board of directors has the power to issue such
shares without shareholder  approval. We fully intend to issue additional common
shares in order to raise  capital  to fund our  business  operations  and growth
objectives.

WE DO NOT ANTICIPATE PAYING DIVIDENDS TO COMMON  STOCKHOLDERS IN THE FORESEEABLE
FUTURE, WHICH MAKES INVESTMENT IN OUR STOCK SPECULATIVE OR RISKY.

We have not paid  dividends  on our common  stock and do not  anticipate  paying
dividends on our common stock in the foreseeable  future. The board of directors
has sole authority to declare dividends  payable to our  stockholders.  The fact
that we have not and do not plan to pay dividends indicates that we must use all
of  our  funds  generated  by  operations  for   reinvestment  in  our  business
activities.  Investors  also must  evaluate an  investment  in PBI solely on the
basis of anticipated capital gains.

LIMITED  LIABILITY  OF OUR  EXECUTIVE  OFFICERS  AND  DIRECTORS  MAY  DISCOURAGE
SHAREHOLDERS FROM BRINGING A LAWSUIT AGAINST THEM.

Our Memorandum and Articles of Incorporation  contain  provisions that limit the
liability of our directors for monetary damages and provide for  indemnification
of officers and directors.  These  provisions may discourage  shareholders  from
bringing a lawsuit against officers and directors for breaches of fiduciary duty
and may reduce the  likelihood of  derivative  litigation  against  officers and
directors even though such action, if successful, might otherwise have benefited
the  shareholders.  In  addition,  a  shareholder's  investment  in  PBI  may be
adversely  affected  to the extent  that we pay costs of  settlement  and damage
awards against officers or directors pursuant to the indemnification  provisions
of the bylaw.  The impact on a shareholder's  investment in terms of the cost of
defending a lawsuit may deter the shareholder  from bringing suit against any of
our officers or directors.  We have been advised that the SEC takes the position
that these  article  and bylaw  provisions  do not affect the  liability  of any
director under applicable federal and state securities laws.

LIMITED MARKET DUE TO PENNY STOCK

The Company's stock differs from many stocks, in that it is a "penny stock." The
Securities  and  Exchange  Commission  has adopted a number of rules to regulate
"penny  stocks."  These rules  include,  but are not limited to,  Rules  3a5l-l,
15g-1,  15g-2,  15g-3,  15g-4,  15g-5,  15g-6 and 15g-7 under the Securities and
Exchange Act of 1934, as amended.  Because our  securities  probably  constitute
"penny stock"  within the meaning of the rules,  the rules would apply to us and
our securities.  The rules may further affect the ability of owners of our stock
to sell their securities in any market that may develop for them. There may be a
limited   market  for  penny   stocks,   due  to  the   regulatory   burdens  on
broker-dealers.  The market among dealers may not be active.  Investors in penny
stock  often are  unable to sell  stock  back to the  dealer  that sold them the
stock. The mark-ups or commissions  charged by the broker-dealers may be greater
than any profit a seller may make.  Because of large dealer  spreads,  investors
may be unable to sell the stock immediately back to the dealer at the same price
the dealer sold the stock to the  investor.  In some  cases,  the stock may fall
quickly in value.  Investors  may be unable to reap any profit  from any sale of
the  stock,  if they  can sell it at all.  Stockholders  should  be aware  that,
according to the Securities and Exchange  Commission  Release No. 34- 29093, the
market for penny stocks has suffered in recent years from  patterns of fraud and
abuse.  These patterns include:  - Control of the market for the security by one
or a few broker-  dealers that are often  related to the  promoter or issuer;  -
Manipulation of prices through  prearranged  matching of purchases and sales and
false and misleading  press releases;  - "Boiler room" practices  involving high
pressure sales tactics and unrealistic price projections by inexperienced  sales
persons;  -  Excessive  and  undisclosed  bid-ask  differentials  and markups by
selling broker- dealers;  and - The wholesale  dumping of the same securities by
promoters and broker-  dealers after prices have been  manipulated  to a desired
level,  along with the  inevitable  collapse  of those  prices  with  consequent


                                       9
<PAGE>

investor losses. Furthermore, the "penny stock" designation may adversely affect
the  development  of any public market for the Company's  shares of common stock
or, if such a market develops, its continuation.  Broker-dealers are required to
personally  determine  whether an  investment  in "penny  stock" is suitable for
customers.  Penny  stocks  are  securities  (i) with a price of less  than  five
dollars per share; (ii) that are not traded on a "recognized" national exchange;
(iii)  whose  prices  are not quoted on the NASDAQ  automated  quotation  system
(NASDAQ-listed  stocks must still meet  requirement  (i)  above);  or (iv) of an
issuer with net tangible  assets less than $2,000,000 (if the issuer has been in
continuous  operation for at least three years) or $5,000,000  (if in continuous
operation for less than three years),  or with average  annual  revenues of less
than $6,000,000 for the last three years. Section 15(g) of the Exchange Act, and
Rule 15g-2 of the Commission require  broker-dealers  dealing in penny stocks to
provide potential investors with a document disclosing the risks of penny stocks
and to obtain a manually signed and dated written receipt of the document before
effecting any transaction in a penny stock for the investor's account. Potential
investors  in the  Company's  common  stock are  urged to  obtain  and read such
disclosure  carefully before  purchasing any shares that are deemed to be "penny
stock." Rule 15g-9 of the Commission requires broker- dealers in penny stocks to
approve the  account of any  investor  for  transactions  in such stocks  before
selling  any  penny  stock  to  that  investor.   This  procedure  requires  the
broker-dealer to (i) obtain from the investor information  concerning his or her
financial  situation,  investment  experience  and investment  objectives;  (ii)
reasonably  determine,  based on that  information,  that  transactions in penny
stocks are  suitable  for the  investor  and that the  investor  has  sufficient
knowledge and experience as to be reasonably  capable of evaluating the risks of
penny stock  transactions;  (iii) provide the investor with a written  statement
setting forth the basis on which the  broker-dealer  made the  determination  in
(ii) above;  and (iv) receive a signed and dated copy of such statement from the
investor,  confirming  that it  accurately  reflects  the  investor's  financial
situation,  investment  experience and investment  objectives.  Compliance  with
these requirements may make it more difficult for the Company's  stockholders to
resell their shares to third parties or to otherwise dispose of them.

Shareholders  should  be  aware  that,  according  to  Securities  and  Exchange
Commission  Release No.  34-29093,  the market for penny  stocks has suffered in
recent years form patterns of fraud and abuse. Such patterns include (i) control
of the market for the  security  by one or a few  broker-dealers  that are often
related  to  the  promoter  or  issuer;  (ii)  manipulation  of  prices  through
prearranged  matching  of  purchases  and sales and false and  misleading  press
releases;  (iii) boiler room practices involving high-pressure sales tactics and
unrealistic price projections by inexperienced sales persons; (iv) excessive and
undisclosed bid-ask differential and markups by selling broker-dealers;  and (v)
the wholesale  dumping of the same  securities  by promoters and broker  dealers
after prices have been manipulated to a desired level,  along with the resulting
inevitable  collapse of those prices and with consequent  investor  losses.  The
Company's  management is aware of the abuses that have occurred  historically in
the penny stock market. Although the Company does not expect to be in a position
to dictate the behavior of the market or of broker  dealers who  participate  in
the market,  management will strive within the confines of practical limitations
to prevent the  described  patterns form being  established  with respect to the
Company's securities.

POSSIBLE NEED FOR ADDITIONAL FINANCING.  The Company has very limited funds, and
such funds,  may not be adequate to take  advantage  of any  available  business
opportunities.  Even if the  Company's  currently  available  funds  prove to be
sufficient to pay for its operations until it is able to acquire an interest in,
or complete a transaction with, a business opportunity,  such funds will clearly
not be sufficient to enable it to exploit the  opportunity.  Thus,  the ultimate
success of the Company  will depend,  in part,  upon its  availability  to raise
additional  capital.  In the event that the Company  requires  modest amounts of
additional  capital  to fund  its  operations  until  it is able to  complete  a
business acquisition or transaction,  such funds, are expected to be provided by
the  principal  shareholders.  However,  the  Company has not  investigated  the
availability,  source,  or  terms  that  might  govern  the  acquisition  of the
additional  capital  which is  expected  to be  required  in order to  exploit a
business  opportunity,  and will not do so until it has  determined the level of
need for  such  additional  financing.  There is no  assurance  that  additional
capital  will be  available  from any  source or, if  available,  that it can be
obtained on terms  acceptable to the Company.  If not  available,  the Company's
operations  will be  limited  to those  that  can be  financed  with its  modest
capital.

NO  OPERATING  HISTORY.  The Company has no  operating  history,  revenues  from
operations  or assets.  The Company faces all of the risks of a new business and



                                       10
<PAGE>

the special risks inherent in the investigation,  acquisition, or involvement in
a new  business  opportunity.  The Company must be regarded as a new or start-up
venture with all of the unforeseen costs,  expenses,  problems, and difficulties
to which such ventures are subject.

NO ASSURANCE OF SUCCESS OR PROFITABILITY. There is no assurance that the Company
will acquire a favorable business opportunity. Even if the Company should become
involved in a business opportunity,  there is no assurance that it will generate
revenues  or  profits,  or that the market  price of the  Company's  outstanding
shares will be increased thereby.

POSSIBLE  BUSINESS  NOT  IDENTIFIED  AND  HIGHLY  RISKY.  The  Company  has  not
identified and has no  commitments to enter into or acquire a specific  business
opportunity. As a result, it is only able to make general disclosures concerning
the risks and hazards of acquiring a business opportunity, rather than providing
disclosure  with respect to specific risks and hazards  relating to a particular
business opportunity.  As a general matter, prospective investors can expect any
potential business opportunity to be quite risky.

TYPE OF BUSINESS  ACQUIRED.  The type of business to be acquired may be one that
desires to avoid effecting its own public offering an the accompanying  expense,
delays,  uncertainties,  and federal  and state  requirements  which  purport to
protect investors.  Because of the Company's limited capital,  it is more likely
than not that any  acquisition  by the Company will involve  other parties whose
primary  interest is the  acquisition of control of a publicly  traded  Company.
Moreover,  any business  opportunity  acquired may be currently  unprofitable or
present other negative factors.

IMPRACTICABILITY  OF EXHAUSTIVE  INVESTIGATION.  The Company's limited funds and
lack of full-time  management will make it  impracticable  to conduct a complete
and exhaustive  investigation and analysis of a business  opportunity before the
Company commits its capital or other resources  thereto.  Management  decisions,
therefore, will likely be made without detailed feasibility studies, independent
analysis,  market  surveys  and the like  which,  if the  Company had more funds
available to it, would be desirable.  The Company will be particularly dependent
in making decisions upon information provided by the promoter,  owner,  sponsor,
or  others  associated  with the  business  opportunity  seeking  the  Company's
participation.  A significant  portion of the Company's  available  funds may be
expended for  investigative  expenses and other expenses  related to preliminary
aspects of completing an  acquisition  transaction,  whether or not any business
opportunity investigated is eventually acquired.

LACK OF  DIVERSIFICATION.  Because of the limited  financial  resources that the
Company  has, it is  unlikely  that the Company  will be able to  diversify  its
acquisitions or operations.  The Company's  probable  inability to diversify its
activities  into  more  than one area  will  subject  the  Company  to  economic
fluctuations within a particular business or industry and therefore increase the
risks associated with the Company's operations.

NEED  FOR  AUDITED  FINANCIAL  STATEMENTS.  The  Company  will  require  audited
financial  statements  from any business that it proposes to acquire.  Since the
Company will be subject to the reporting  provisions of the Securities  Exchange
Act of 1934,  as amended  (the  Exchange  Act),  it will be  required to include
audited financial statements in its periodical reports for any existing business
it may acquire.  In addition,  the lack of audited  financial  statements  would
prevent the  securities  of the Company  from  becoming  eligible for listing on
NASDAQ,  the  automated   quotation  system  sponsored  by  the  Association  of
Securities Dealers, Inc., or on any existing stock exchange.  Moreover, the lack
of such  financial  statements  is  likely  to  discourage  broker-dealers  from
becoming  or  continuing  to serve as  market  makers in the  securities  of the
Company. Finally, without audited financial statements, the Company would almost
certainly be unable to offer securities under a registration  statement pursuant
to the  Securities  Act of 1933, and the ability of the Company to raise capital
would be significantly limited. Consequently, acquisitions prospects that do not
have, or are unable to provide  reasonable  assurances that they will be able to
obtain,  the required audited  statements would not be considered by the Company
to be appropriate for acquisition.

OTHER  REGULATION.  An acquisition made by the Company may be of a business that
is subject to regulation or licensing by federal,  state, or local  authorities.
Compliance  with  such  regulations  and  licensing  can  be  expected  to  be a
time-consuming,  expensive process and may limit other investment  opportunities
of the Company.

DEPENDENCE UPON MANAGEMENT;  LIMITED  PARTICIPATION  OF MANAGEMENT.  The Company
will be entirely  dependant upon the experience of its officers and directors in
seeking,  investigating,  and  acquiring  a  business  and in  making  decisions
regarding the Company's operations.  It is possible that, from time to time, the


                                       11
<PAGE>

inability  of such  persons to devote  their full time  attention to the Because
investors  will not be able to evaluate the merits of possible  future  business
acquisitions  by the  Company,  they should  critically  assess the  information
concerning the Company's officers and directors. (See Management.)

LACK OF  CONTINUITY  IN  MANAGEMENT.  The  Company  does not have an  employment
agreement  with any of its officers or directors,  and as a result,  there is no
assurance  that they will  continue  to manage  the  Company in the  future.  In
connection with acquisition of a business opportunity,  it is likely the current
officers and  directors of the Company may resign.  A decision to resign will be
based  upon the  identity  of the  business  opportunity  and the  nature of the
transaction,  and is  likely  to  occur  without  the  vote  or  consent  of the
stockholders of the Company.

INDEMNIFICATION OF OFFICERS AND DIRECTORS. The Company's By-Laws provide for the
indemnification  of its,  directors,  officers,  employees,  and  agents,  under
certain  circumstances,  against  attorney's fees and other expenses incurred by
them in any  litigation  to  which  they  become  a  party  arising  from  their
association  with or activities on behalf of the Company.  The Company will also
bear  the  expenses  of  such  litigation  for any of its  directors,  officers,
employees, or agents, upon such persons promise to repay the Company therefor if
it is ultimately determined that any such person shall not have been entitled to
indemnification.   This  indemnification  policy  could  result  in  substantial
expenditures by the Company, which it may be unable to recoup.

DEPENDENCE UPON OUTSIDE ADVISORS.  To supplement the business  experience of its
officers  and  directors,  the Company  may be  required to employ  accountants,
technical experts, appraisers,  attorneys, or other consultants or advisors. The
selection of any such advisors will, be made by the Company's officers,  without
any input by shareholders.  Furthermore, it is anticipated that such persons may
be  engaged  on an as needed  basis  without  a  continuing  fiduciary  or other
obligation to the Company.  In the event the officers of the Company consider it
necessary  to hire  outside  advisors,  they may elect to hire  persons  who are
affiliates, if those affiliates are able to provide the required services.

LEVERAGED  TRANSACTIONS.  There  is a  possibility  that  any  acquisition  of a
business  opportunity  by the Company  may be  leveraged,  i.e.  the Company may
finance the  acquisition of the business  opportunity  by borrowing  against the
assets of the  business  opportunity  to be acquired,  or against the  projected
future revenues or profits of the business opportunity.  This could increase the
Company's exposure to larger losses. A business  opportunity  acquired through a
leveraged  transaction  is profitable  only if it generates  enough  revenues to
cover the  related  debt and  expenses.  Failure  to make  payments  on the debt
incurred to purchase  the  business  opportunity  could  result in the loss of a
portion or all of the assets  acquired.  There is no assurance that any business
opportunity  acquired through a leveraged  transaction will generate  sufficient
revenues to cover the related debt and expenses.

COMPETITION.  The search for potentially  profitable  business  opportunities is
intensely  competitive.  The  Company  expects  to  be  at a  disadvantage  when
competing  with  many  firms  that  have  substantially  greater  financial  and
management  resources  and  capabilities  than the  Company.  These  competitive
conditions  will  exist  in  any  industry  in  which  the  Company  may  become
interested.

NO FORESEEABLE DIVIDENDS. The Company has not paid dividends on its Common Stock
and does not anticipate paying such dividends in the foreseeable future.

LOSS OF CONTROL BY PRESENT  MANAGEMENT AND  STOCKHOLDERS.  In  conjunction  with
completion of a business  acquisition,  it is anticipated  that the Company will
issue an amount of the  Company's  authorized  but  unissued  Common  Stock that
represents  the greater  majority of the voting power and equity of the Company.
In  conjunction  with  such  a  transaction,  the  Company's  current  Officers,
Directors,  and  principal  shareholders  could also sell all, or a portion,  of
their controlling block of stock to the acquired Company's stockholders.  Such a
transaction  would result in a greatly  reduced  percentage  of ownership of the
Company  by its  current  shareholders.  As a  result,  the  acquired  Company's
stockholders would control the Company, and it is likely that they would replace
the Company's management with persons who are unknown at this time.

NO PUBLIC MARKET  EXISTS.  There is currently no public market for the Company's
common stock, and no assurance can be given that a market will develop or that a
shareholder will ever be able to liquidate his investment  without  considerable
delay, if at all. If a market should develop,  the price may be highly volatile.
Factors  such as  those  discussed  in this  Risk  Factors  section  may  have a
significant impact upon the market price of the securities offered hereby. Owing
to the low price of the  securities,  many brokerage firms may not be willing to
effect  transactions  in the  securities.  Even if a  purchasers  finds a broker
willing  to  effect a  transaction  in theses  securities,  the  combination  of



                                       12
<PAGE>

brokerage commissions, state transfer taxes, if any, and any other selling costs
may exceed the selling price. Further, many leading institutions will not permit
the use of such securities as collateral for any loans.

RULE 144 SALES. Of the 116,195,645 presently outstanding shares of the Company's
stock. 100,000,000 shares are "restricted securities" within the meaning of Rule
144 under the Securities Act of 1933, as amended.  As restricted  shares,  these
shares may be resold only  pursuant to an  effective  registration  statement or
under the  requirements of Rule 144 or other  applicable  state  securities law.
Rule 144  provides in essence that a person who has held  restricted  securities
for a prescribed period, may under certain conditions,  sell every three months,
in brokerage  transactions,  a number of shares that does not exceed the greater
of 1.0% of a company's  outstanding  common stock or the average  weekly trading
volume  during the four calendar  weeks prior to sale.  There is no limit on the
amount of restricted  securities that may be sold by a  non-affiliate  after the
restricted  securities have been held by the owner, for a period of at least two
years.  A sale  under Rule 144,  or under an other  exemption  from the Act,  if
available,  or pursuant to subsequent  registrations  of common stock of present
shareholders, may have a depressive effect upon the price of the Common Stock in
may market that may develop. As of the date hereof, the current owners have held
699,627 of the outstanding shares of the common stock of the Company thereof for
a  period  of more  than two  years.  Accordingly,  such  shares  are  currently
available for resale in accordance with the provisions of Rule 144.

BLUE SKY  CONSIDERATION.  Because the securities  registered  hereunder have not
been registered for resale under the Blue Sky laws of any state,  the holders of
such shares and persons who desire to purchase  them in any trading  market that
might  develop in the  future,  should be aware,  that there may be  significant
state  Blue Sky law  restrictions  upon the  ability  of  investors  to sell the
securities and of purchasers to purchase the securities.  Accordingly, investors
should  consider  the  secondary  market for the  Company's  securities  to be a
limited one.

Item 2. Description of Property.

Our principal  business  address is 1518 West Hastings St.,  Vancouver,  British
Columbia,  Canada.  During the fiscal year ending  March 31,  2006,  office rent
totaled  $6,000.  The office rent has been and will be treated as a component of
additional  paid in  capital.  The  corporate  office  rent for the fiscal  year
beginning April 1, 2006 will be $1,000 monthly.

Item 3.    Legal Proceedings.

The Company is not a party to any pending legal proceeding.

Item 4.    Submission of Matters to a Vote of Security Holders.

No  matter  was  submitted  to a  vote  of the  security  holders,  through  the
solicitation  of proxies or otherwise,  during the fourth  quarter of the fiscal
year covered by this report.



                                       13
<PAGE>

                                     PART II

Item 5. Market for Common Equity, Related Stockholder Matters and Small Business
        Issuer Purchases of Equity Securities.

(a) Market Information.

Our common stock trades  Over-the-Counter  (OTC) on the NASD Electronic Bulletin
Board  under  the  symbol  GIMU.  Table 1 sets  forth  the  high  and  low  sale
information  for  fiscal  years  2006  and  2005.   These   quotations   reflect
inter-dealer prices, without retail mark-up, mark-down or commission and may not
represent actual transactions.

Table 1.

Sale Information


Fiscal Quarter Ended                High                      Low


March 31, 2006                      0.16                      0.16
December 31, 2005                   0.25                      0.17
September 30, 2005                  0.28                      0.20
June 30, 2005                       0.35                      0.31

March 31, 2005                      0.34                      0.30
December 31, 2004                   0.09                      0.09
September 30, 2004                  0.16                      0.145
June 30, 2004                       0.38                      0.25

(a)      Holders.

Our company has  approximately  31  shareholders of its common stock as of March
31, 2006 holding 116,195,645 common shares.

(b)      Dividends.

There are no  restrictions  imposed on the  Company  which  limit its ability to
declare or pay  dividends on its common stock,  except for  corporate  state law
limitations.  No cash  dividends have been declared or paid to date and none are
expected to be paid in the foreseeable future.

(c)      Recent Sales of Unregistered Securities

During the fiscal year ending March 31, 2006,  the Company  offered and sold the
following  securities  pursuant to a securities  transaction  exemption from the
registration requirements of the Securities Act of 1933, as amended.

On June 17, 2005, the Company issued 100,000,000 common shares in the name of G.
Jensen  Trustee  for the Taurus  Trust.  The shares  were  issued in trust for a
proposed  acquisition of the rights to the drug  Trioxolane.  Under the terms of
the transaction,  the Company issued  100,000,000  common shares in trust, which
were  held  in  escrow  subject  to  the  completion  of  the  acquisition.  The
transaction  was not  completed  and the  common  shares  were  returned  to the
corporate  treasury.  The  Company  is in the  process of  cancelling  the share
certificates.

The securities issued above were issued in a private transaction pursuant to
Section 4(2) of the Securities Act of 1933, as amended, (the "Securities Act").
These shares are considered restricted securities and may not be publicly resold
unless registered for resale with appropriate governmental agencies or unless
exempt from any applicable registration requirements.

(d)      Securities  Authorized  for Issuance under Equity  Compensation  Plans:
         None





                                       14
<PAGE>

Item 6. Management's  Discussion and Analysis of Financial Condition and Results
        of Operation or Plan of Operation.

When used in this Form 10-KSB and in our future  filings with the Securities and
Exchange  Commission,  the  words or  phrases  will  likely  result,  management
expects,  or we expect,  will  continue,  is  anticipated,  estimated or similar
expressions  are  intended to  identify  forward-looking  statements  within the
meaning of the Private  Securities  Litigation  Reform Act of 1995.  Readers are
cautioned not to place undue  reliance on any such  forward-looking  statements,
each of which speak only as of the date made.  These  statements  are subject to
risks and uncertainties,  some of which are described below.  Actual results may
differ  materially from historical  earnings and those presently  anticipated or
projected. We have no obligation to publicly release the result of any revisions
that may be made to any forward-looking statements to reflect anticipated events
or circumstances occurring after the date of such statements.

A. OPERATING RESULTS

The  following  discussion  and  analysis  is  based  on and  should  be read in
conjunction with the Company's audited financial  statements including the notes
thereto and other financial  information appearing elsewhere herein. The audited
financial statements have been prepared using Canadian dollars and are presented
in accordance with accounting principles generally accepted in Canada.

U.S. AND CANADIAN GAAP DIFFERENCES

The financial  statements  have been prepared in accordance  with Canadian GAAP,
which conform in all material respects with those of the US and are disclosed in
note 3 to the audited financial statements of the Company for March 31, 2006 and
2005.

RESULTS OF OPERATIONS - YEAR TO YEAR COMPARISONS BETWEEN 2006 AND 2005

For the year ended March 31, 2006 the Company  achieved  sales  revenues of $-0-
compared  with sales  revenues of $-0- for the period ended March 31, 2005.  The
Company's  net loss for the year was $111,919 in 2006  compared to net income of
$59,377 in 2005. Such increase in the net loss was due primarily to no revenues,
continued corporate  expenses.  As of the year ended March 31, 2006, the Company
had an accumulated stockholders' deficiency of $(5,541,404).  The current year's
contribution  to the  deficit was  financed in part by sums  advanced by related
parties and other payables.

B. LIQUIDITY AND CAPITAL RESOURCES

YEAR ENDED MARCH 31, 2006 COMPARED WITH THE YEAR ENDED MARCH 31, 2005

The Company's total assets decreased from $10,155 in 2005 to $165 in 2006.

The Company's overall liabilities increased from $459,117 in 2005 to $521,046 in
2006 due in a large part to an increase in related party loans.

In  2006,  the  working  capital  deficiency  increased  to  $(520,881)  from  a
deficiency of $(448,962) in 2005.

The Company has had no significant  operations  during the last fiscal year and,
accordingly,  is fully  dependent  either future sales of securities or upon its
current  management and, or advances or loans from  significant  stockholders or
corporate  officers  to  provide  sufficient  working  capital to  preserve  the
integrity of the corporate entity.

There is no assurance that the Company will be able to obtain additional funding
through the sales of additional  securities or, that such funding, if available,
will be obtained on terms  favorable to or affordable by the Company.  It is the
intent of management and significant  stockholders to provide sufficient working
capital necessary to support and preserve the integrity of the corporate entity.
However,  there is no legal  obligation  for either  management  or  significant
stockholders to provide additional future funding.



                                       15
<PAGE>

We will  need to raise  capital  in  order to  commence  our  proposed  business
operations.  No assurance can be given that we will be able to raise  sufficient
capital to implement any proposed  business  operations.  We have not identified
any specific future financing sources. In the future, our efforts to finance the
Company  may result in the  issuance  of equity and debt  instruments.  This and
other  future  financing  activity,  if  any,  may  result  in the  dilution  of
shareholder  equity.  We expect to incur  financial  losses for the  foreseeable
future.

The Company has no residual  capital  commitment in respect to its  discontinued
operations and has no current capital commitments.

US GAAP VERSUS CANADIAN GAAP

Under Canadian GAAP applicable to junior mining exploration  companies,  mineral
exploration  expenditures  on prospective  properties may be deferred until such
time as it is determined  that further  exploration is not  warranted,  at which
time  the  property  costs  are  written-off.  Under US  GAAP,  all  exploration
expenditures  must be  expensed  until  an  independent  feasibility  study  has
determined that the property is capable of economic commercial production.

There were no  property  costs  incurred  or written off during the 2006 or 2005
fiscal  year and  accordingly  the  differences  between  the  allowable  US and
Canadian GAAP treatments of property costs would result in no change in net loss
under U.S. GAAP from that reported under Canadian GAAP.

OFF-BALANCE SHEET ARRANGEMENTS:  None

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK:

The  Company  does  not  issue  or  invest  in  financial  instruments  or their
derivatives for trading or speculative  purposes.  The limited operations of the
Company are conducted  primarily in the Canada, and, are not subject to material
foreign  currency  exchange risk.  Although the Company has outstanding debt and
related  interest  expense,  market risk of interest rate exposure in the United
States is currently not material.







                                       16
<PAGE>

Item 7.  Financial Statements.

The  audited  financial  statements  for  the  Company  have  been  prepared  in
accordance with accounting  principles  generally accepted in Canada.  There are
three differences between accounting  principles generally accepted in Canada as
opposed to those generally accepted in the United States that affect the Company
and these are: stock compensation on escrow shares, weighted average outstanding
shares for loss per share calculations,  and capitalization of resource property
costs.

With  respect to escrow  shares:  in Canada,  when  escrow  shares are issued at
nominal prices and are released from escrow no compensation  expense is recorded
whereas in the US,  such  release  triggers a  compensation  which  affects  the
compensation expense and the share capital.

With  respect  to the  weighted  average  outstanding  shares for loss per share
calculations:  in Canada, the weighted average outstanding shares include escrow
shares  issued but not  released,  whereas  in the US, the escrow  shares do not
enter into the calculation until released from escrow.

With respect to resource  property costs:  in Canada all  exploration  costs for
properties to which a company retains title and continues  exploration  work are
capitalized  and put on the  balance  sheet  whereas  in the US such  costs  are
expensed  annually  unless  there is an  engineering  report on hand  which will
determine a net realizable value to justify the capitalization.

The audited financial statements for the Company for March 31, 2006 and 2005 are
attached hereto and form a material part of this Annual Report.


Item  8.  Changes  In and  Disagreements  with  Accountants  on  Accounting  and
          Financial Disclosure.

On July 19, 2006, our former independent certifying accountant, Smythe Ratcliff,
LLP, resigned. On July 19, 2006, we engaged James Stafford Chartered Accountants
to replace Smythe Ratcliffe, LLP.

The financial  statements reported on by Smythe Ratcliffe,  LLP were not subject
to an adverse or  qualified  opinion,  or a  disclaimer  of opinion and were not
modified as to uncertainty, audit scope or accounting principles during the past
two fiscal years, and interim periods, with the exception that Smythe Ratcliffe,
LLP did issue a going  concern  opinion  which  appears Note 2 of the  Company's
financial  statements  which are a part of the Form 20-F  Annual  Report for the
period ending March 31, 2005.








                                       17
<PAGE>

Item 8A. Controls and Procedures.

(a)      Evaluation of Disclosure Controls and Procedures.

As of the end of the  reporting  period,  March  31,  2006,  we  carried  out an
evaluation,  under the supervision and with the participation of our management,
including  the  Company's   Chairman  and  Chief   Executive   Officer/Principal
Accounting  Officer,  of the  effectiveness  of the design and  operation of our
disclosure  controls and procedures pursuant to Rule 13a-15(e) of the Securities
Exchange  Act of 1934  (the  "Exchange  Act"),  which  disclosure  controls  and
procedures are designed to insure that information required to be disclosed by a
company  in the  reports  that it files  under  the  Exchange  Act is  recorded,
processed, summarized and reported within required time periods specified by the
SEC's rules and forms.  Based upon that  evaluation,  the Chairman and the Chief
Financial  Officer  concluded  that our  disclosure  controls and procedures are
effective  in timely  alerting  them to  material  information  relating  to the
Company  required to be included in the  Company's  period SEC filings.  We have
been unable to timely file our  periodic  reports due to the lack of  sufficient
money to pay our  independent  certifying  accountants.  We were late filing our
annual  report on Form 10-KSB for the fiscal year ending  March 31, 2006 and our
quarterly report on Form 10-QSB for the period ending June 30, 2006.





















                                       18
<PAGE>

(b)      Changes in Internal Control.

Subsequent to the date of such evaluation as described in  subparagraph(a)above,
there were no changes  in our  internal  controls  or other  factors  that could
significantly affect these controls, including any corrective action with regard
to significant deficiencies and material weaknesses.

(c)      Limitations.

Our  management,   including  our  Principal  Executive  Officer  and  Principal
Financial  Officer,  does not expect  that our  disclosure  controls or internal
controls over  financial  reporting  will prevent all errors or all instances of
fraud.  However,  we believe that our  disclosure  controls and  procedures  are
designed to provide reasonable assurance of achieving this objective.  A control
system,  no matter how well designed and operated,  can provide only reasonable,
not  absolute,  assurance  that the  control  system's  objectives  will be met.
Further,  the design of a control  system  must  reflect the fact that there are
resource  constraints,  and the benefits of controls must be considered relative
to their costs.  Because of the inherent  limitations in all control systems, no
evaluation of controls can provide  absolute  assurance  that all control issues
and instances of fraud,  if any,  within our company have been  detected.  These
inherent limitations include the realities that judgments in decision-making can
be faulty,  and that  breakdowns  can occur  because of simple error or mistake.
Controls can also be  circumvented  by the individual  acts of some persons,  by
collusion of two or more people, or by management override of the controls.  The
design of any system of controls is based in part upon certain assumptions about
the likelihood of future events, and any design may not succeed in achieving its
stated goals under all  potential  future  conditions.  Over time,  controls may
become  inadequate  because of changes in  conditions  or  deterioration  in the
degree of  compliance  with  policies  or  procedures.  Because of the  inherent
limitation of a  cost-effective  control system,  misstatements  due to error or
fraud may occur and not be detected.

ITEM 8B. Other Information

Change in Corporate Domicile
----------------------------

On February 28, 2006,  the Company  changed its corporate  domicile from British
Columbia,  Canada to the State of Wyoming, USA. The Company filed an application
for  certificate  of  registration  and articles of  continuance in the State of
Wyoming.  The British Columbia  corporation was formally dissolved June 2, 2006.
The Company has ceased to be a classified as a foreign issuer.

Change in Foreign Issuer Status
-------------------------------

As a result of our change in domicile from British Columbia, Canada to the State
of Wyoming we were no longer eligible for "foreign issuer" status. Prior to this
change in domicile  we filed  annual  reports on Form 20-F and other  reports on
Form 6-K. Commencing with our annual report for the fiscal year ending March 31,
2006, we are filing our annual report on Form 10-KSB.  All  subsequent  periodic
reports will follow U.S. issuer  requirements under the Securities  Exchange Act
of 1934, as amended.

Proposed Business Combination Transaction
-----------------------------------------

On July 19, 2006, the Company entered into a securities  exchange agreement with
MediPri Limited, Primemedical International, Ltd.("MedPri")and Medical Monitors,
("MML").  Under  the  terms  of the  agreement,  the  Company  agreed  to  issue
Primemedical International, Ltd.("PML") the following securities:

(a) a total of 74,000,000 common shares;

(b) a total of 7,400,000 share purchase  warrants where each warrant  represents
the right to  purchase  one common  share of the Company at a price of $0.50 USD
for a period of five years from the date of the Agreement;

(c) A promissory  note in the amount of $10,000,000  payable  automatically  and
without  demand  on the third  anniversary  of the date of the  Agreement.  This
promissory note is to be non-interest bearing and convertible into common shares
of the Company at the holder's  option at any time prior to the  maturity  date,
the conversion  amount is to be at a price equal to  eighty-five  percent of the
average closing price of the Company's common shares over the five business days
immediately  preceding  the  date  of the  conversion.  At no  time  shall  such
conversion price be less than $0.40USD or greater than $ 1.00 USD;



                                       19
<PAGE>

(d) A promissory note issued to Medical  Monitors,  Limited in consideration for
intellectual  property,   bearing  no  interest,  in  the  principle  amount  of
$4,000,000  USD,  payable   automatically   and  without  demand  on  the  first
anniversary of the date of this agreement.  Such note shall be convertible  into
common  shares of the  Company at the  holder's  option at any time prior to the
maturity date, such conversion to be at a price equal to eighty-five  percent of
the average  closing price of the Company's  common shares over the  immediately
preceding  five business  days. At no time shall such  conversion  price be less
than $0.40 USD or greater  than $1.00 USD. In exchange  for the  issuance by the
Company to PML of the Company's  shares,  warrants,  and promissory  notes,  PML
shall assign and convey to the Company all of its interest in 58,302,000  shares
of common stock of MedPri.  Such shares are to constitute all of the outstanding
capital stock of MedPri.

This is a pending transaction and subject to the various performance obligations
of the parties.

                                    PART III

Item 9. Directors, Executive Officers, Promoters and Control Persons; Compliance
        with Section 16(a) of the Exchange Act.

The  following  table sets forth the officers and directors of the Global Immune
Technologies, Inc.

(a)      Directors and Executive Officers

The following  table sets forth the name, age, and position of each Director and
Executive Officer of Global Immune Technologies Inc:

NAME                   AGE       POSITION                     Term of Office

Donald L. Perks        54        President, CFO, Director     8/15/05-Present

Piers VanZiffle        59        Director                     8/30/05 to 9-15-06

Donald L.  Perks:  President/Director  - elected  at AGM  September  17,  2003 -
resigned May 9, 2005 - reappointed August 15, 2005

Piers VanZiffle: Director - Appointed August 30, 2005, resigned September 2006.

The  directors  of the Company are  elected by the  shareholders  at each annual
general  meeting  of the  Company,  or,  in the  event  of a  vacancy,  they are
appointed  by the Board of  Directors  then in office,  to serve  until the next
annual general meeting of the Company or until their  successors are elected and
ratified.  The  Company's  executive  officers  are  appointed  by the  Board of
Directors and serve at the discretion of the Board of Directors.

There are no arrangements or  understandings  between the directors and officers
of Global Immune  Technologies,  Inc. and any other person pursuant to which any
director  or officer  was or is to be  selected  as a director  or  officer.  In
addition,  there  are no  agreements  or  understandings  for  the  officers  or
directors  to  resign at the  request  of  another  person  and the  above-named
officers and  directors  are not acting on behalf of nor acting at the direction
of any other person.

The following summary outlines the professional  background of the directors and
executive officers of the Company.

Donald  Perks,  President,  CFO and  member  of the  board  of  directors  is an
independent  businessman and is a self-employed  Business Consultant.  Mr. Perks
founded Canada Pay Phone and was active in the success of that company from 1994
to 2001. He has been actively  managing  Global Immune  Technologies  Inc. since
2003.





                                       20
<PAGE>

Piers  VanZiffle,  Director,  is an  independent  businessman  and  has  been  a
self-employed  Business  Consultant  for the past  eight  years.  Mr.  VanZiffle
resigned his position with the Company on September 15, 2006.

(b)      Identify Significant Employees. None.

(c)      Family Relationships. None known.

(d)      Involvement  in  Certain  Legal  Proceedings.  None  of  the  Company's
         directors,  officers,  promoters or control persons, if any, during the
         past five years was, to the best of the Company's knowledge:

1.       A  general  partner  or  executive  officer  of a  business  that had a
         bankruptcy  petition  filed by or  against it either at the time of the
         bankruptcy or within the two years before the bankruptcy;
2.       Convicted  in a  criminal  proceeding  or  been  subject  to a  pending
         criminal  proceeding  (excluding  traffic  violations  and other  minor
         offenses);
3.       Subject to any order,  judgment, or decree, not subsequently  reversed,
         suspended  or  vacated,   of  any  court  of  competent   jurisdiction,
         permanently or temporarily enjoining,  barring, suspending or otherwise
         limiting his or her involvement in any type of business,  securities or
         banking activities; and
4.       Found by a court of competent  jurisdiction  (in a civil  action),  the
         Securities  and Exchange  Commission or the Commodity  Futures  Trading
         Commission  to  have   violated  a  federal  or  state   securities  or
         commodities  law, and the judgment has not been reversed,  suspended or
         vacated.

Compliance with Section 16(a) of the Securities Exchange Act of 1934

During the fiscal  year  ending  March 31,  2006,  the  Company's  officers  and
directors were not subject to Section 16 because the company was classified as a
foreign issuer.

CODE OF ETHICAL CONDUCT.

On October 24, 2006, our board of directors  adopted our code of ethical conduct
that applies to all of our  employees  and  directors,  including  our principal
executive officer,  principal financial officer, principal accounting officer or
controller, and persons performing similar functions.

We believe the adoption of our Code of Ethical  Conduct is  consistent  with the
requirements of the  Sarbanes-Oxley Act of 2002. This Code of Ethical Conduct is
attached to this report as Exhibit 20.

Our Code of Ethical Conduct is designed to deter wrongdoing and to promote:

o        Honest and ethical conduct, including the ethical handling of actual or
         apparent  conflicts  of  interest  between  personal  and  professional
         relationships;
o        Full, fair, accurate,  timely and understandable  disclosure in reports
         and  documents  that we file or submit  to the  Securities  &  Exchange
         Commission and in other public communications made by us;
o        Compliance with applicable governmental laws, rules and regulations,
o        The  prompt  internal  reporting  to an  appropriate  person or persons
         indentified  in the code of violations of our Code of Ethical  Conduct;
         and
o        Accountability for adherence to the Code.


Item 10. Executive Compensation.

The following table sets forth the  compensation  of the executive  officers for
the year ended March 31, 2006.




                                       21
<PAGE>

Summary Compensation Table

                                Annual Compensation   Long-term Compensation
                                -------------------   --------------------------
                   Fiscal       Salary/               Stock
Name               Year         Fees          Bonus   Awards (#)      Options(#)
                                ------------------------------------------------
Don Perks          2006         24,000         -0-      -0-              -0-
Piers VanZiffle    2006          -0-           -0-      -0-              -0-


Note
----
(1)  Mr. Perks annual  salary has been  accounted for as  contributed  services.
     This amount has not been set up as an accrued  payable,  but rather forms a
     component of additional paid in capital.


Item 11. Security Ownership of Certain Beneficial Owners and Management.

Table 1 lists the  persons who are known to the Company to be the owners of more
than five percent of the  Company's  equity  shares  according to the  Company's
records  as of March 31,  2006.  Beneficial  Ownership  of more than 5% based on
116,195,645 common shares.

Beneficial Ownership of 5%.

(a) Our stock transfer agency records do not list any  shareholders  owning five
percent or more of our common stock.

Shareholder Name and Address                Number of Shares    Percentage
                                            Beneficially        Ownership
                                            Owned Common        Beneficially
                                            Shares              Owned Common
                                                                Shares

Garth Jensen Trustee for the Taurus Trust   100,000,000(1)      86.06%
186 Steel St.
Barrie, Ontario
Canada

Notes:  (1) The shares  were issued in trust for a proposed  acquisition  of the
rights to the drug Trioxolane.  Under the terms of the transaction,  the Company
issued  100,000,000 common shares in trust, which were held in escrow subject to
the completion of the  acquisition.  The  transaction  was not completed and the
common  shares were returned to the  corporate  treasury.  The Company is in the
process of cancelling the share certificates.

(b) Security  Ownership of Management.  Based on 116,195,645 shares as set forth
in (a) above as of March 31, 2006.


Table 2.
(1)              (2)                        (3)                 (4)
Title of Class   Name and Address           Amount and Nature   Percent of Class
Common Stock

Donald Perks     1518 West Hastings St.,
                 Vancouver, British Columbia
                 Canada.                           -0-                 -0-


(c)Changes in Control.  The proposed  securities  exchange agreement executed on
July 19, 2006, with MediPri Limited, Primemedical International,  Ltd.("MedPri")
and Medical Monitors Limited ("MML) would result in a change of control when the
transaction  is  completed.  This is a pending  transaction  and  subject to the
various  performance  obligations  of the  parties  which are  incomplete  as of
November 2, 2006.

The Company anticipates that compensation will be provided by the Company during
the Company's next  financial  year to Donald Perks in conjunction  with certain
management and administrative services to be provided to the Company.

LONG TERM  INCENTIVE  PLANS - AWARDS IN MOST RECENTLY  COMPLETED  FINANCIAL YEAR
During its most recently  completed  financial  year, and for the two previously
completed  financial  years, the Company has not awarded or instituted any LTIPs
in favor of its Named Executive Officers.

OPTIONS/SAR GRANTS DURING THE MOST RECENTLY COMPLETED FINANCIAL YEAR
No individual grants of Options to purchase or acquire securities of the Company
or  any  of its  subsidiaries  (whether  or not  in  tandem  with  SARs)  or any
freestanding  SARs were  granted  or were in  effect  and in favor of any of the
Company's Named Executive  Officers during the Company's most recently completed
financial year.




                                       22
<PAGE>

AGGREGATE  OPTIONS/SAR  EXERCISES DURING THE MOST RECENTLY  COMPLETED  FINANCIAL
YEAR AND FINANCIAL YEAR-END OPTION/SAR VALUE: None

DEFINED BENEFIT PLANS
The Company  does not have,  and at no time during its most  recently  completed
financial year had, any defined  benefit or actuarial  plans in respect of which
any of its Named Executive Officers were eligible to participate.

COMPENSATION OF THE COMPANY'S DIRECTORS: None

MANAGEMENT CONTRACTS: None

BOARD PRACTICES

The Board of Directors meets  periodically to set policy and review the progress
of the Company as well as review and approve budgets and expenditures.

The  Directors  of the Company are  elected by the  shareholders  at each annual
general  meeting  of the  Company,  or,  in the  event  of a  vacancy,  they are
appointed  by the Board of  Directors  then in office,  to serve  until the next
annual general meeting of the Company or until their  successors are elected and
ratified.

The  Company's  executive  officers are  appointed by the Board of Directors and
serve at the discretion of the Board of Directors.


Item 12.   Certain Relationships and Related Transactions.

(a)      Transactions with Management and Others.

Mr. Perks annual  salary has been set as $24,000.  This salary has been and will
continue to be treated as  contributed  services  reflected  as a  component  of
additional paid in capital.

Corporate  offices are provided by Donald Perks,  the Company's sole officer and
director.  Office rent is paid to Mr. Perks,  but has been and will be accounted
for as contributed services. The rent has not been accounted for as a payable to
Mr.  Perks,  but rather has been  treated as  additional  paid in  capital.  The
corporate office rent for the fiscal year beginning April 1, 2006 will be $1,000
monthly and accounted for as additional paid in capital.

Donald Perks loaned the Company the sum of $12,835 during the fiscal year ending
March 31, 2006 in order to settle outstanding Company obligations.

Except as otherwise set forth in this report, no member of management, executive
officer, director, nominee for a director or security holder who is known to the
Company to own of record or beneficially  more than five percent of any class of
the Company's voting  securities,  nor any member of the immediate family of any
of the foregoing  persons,  has had any direct or indirect  material interest in
any transaction to which the Company was or is to be a party.

(b)      Certain Business Relationships.

         Except as set forth in (a) above,  and to the knowledge of  management,
or as previously filed in the Company's periodic reports, no director or nominee
for  director  is or has been  related to any person who has been a party to any
transaction with the Company.

(c)      Indebtedness of Management.

No member of the  Company's  management  is or has been  indebted to the Company
since the beginning of its last fiscal year.

(d)      Transactions with Promoters. None.




                                       23
<PAGE>

Item 13. Exhibits

         (a)      Exhibits

         10       Securities   Exchange   Agreement   with   MedPri,    Limited,
                  Primemedical International, Inc.
         20       Code of Ethical Conduct
         31       Chief Executive  Officer-Section 302 Certification pursuant to
                  Sarbanes-Oxley Act.
         32       Chief Executive  Officer-Section 906 Certification pursuant to
                  Sarbanes-Oxley Act.


Item 14. Principal Accounting Fees and Services.

The Company paid or accrued the  following  fees in each of the prior two fiscal
years to its principal accountant.

                                    Year End 3-31-06            Year End 3-31-05

Audit Fees
Audit-related Fees                      $10,482                     $11,290
Tax Fees
All other fees
Total Fees                              $10,482                     $11,290

The Company has no formal audit committee. However, as defined in Sarbanes-Oxley
Act of 2002, the entire Board of Directors is the Company's serves as the
company audit committee.

To our knowledge,  the Company's principal accountant during 2006 did not engage
any other  persons or firms  other than the  principal  accountant's  full-time,
permanent employees.

                                   SIGNATURES

Pursuant to the  requirements of Section 13 or 15(d) of the Securities  Exchange
Act of 1934,  the  registrant  has duly  caused  this report to be signed on its
behalf by the undersigned thereunto duly authorized.

December 13, 2006


Global Immune Technologies, Inc.



 /s/ Donald Perks
--------------------------------
By: Donald Perks
Title: President, CEO, CFO


         In accordance  with the Exchange Act, this report has been signed below
by the following  persons on behalf of the  Registrant and in the capacities and
on the dates indicated.

December 13, 2006



/s/ Donald Perks
--------------------------------
Donald Perks, CEO, CFO, Director










                                       24


<PAGE>






Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)

Financial Statements
(Expressed in Canadian Dollars)
31 March 2006


















<PAGE>

JAMES STAFFORD
--------------------------------------------------------------------------------
                                                James Stafford
                                                Chartered Accountants*
                                                Suite 350-1 1 11 Melville Street
                                                Vancouver, British Columbia
                                                Canada V6E 3V6
                                                Telephone +1 604 669 0177
                                                Facsimile +1 604 669 0754


We have audited the  accompanying  balance sheet of Global  Immune  Technologies
Inc. (the "Company") (formerly Secureview Systems Inc.) as at 31 March 2006, and
the related  statements  of  operations  and deficit,  cash flows and changes in
stockholders' deficiency for the year then ended. These financial statements are
the responsibility of the Company's management. Our responsibility is to express
an opinion on these  financial  statements  based on our audits.  The  financial
statements  of the  Company  as at 31 March  2005,  the  related  statements  of
operations and deficit, cash flows, and changes in stockholders'  deficiency for
the years ended 31 March 2005 and 2004 were  audited by another firm of auditors
whose  report dated 11 October 2005  expressed an  unqualified  opinion on those
statements.

We conducted our audits in accordance with Canadian  generally accepted auditing
standards and the standards of the Public  Company  Accounting  Oversight  Board
(United States of America).  These standards require that we plan and perform an
audit to obtain reasonable  assurance whether the financial  statements are free
of material misstatement. An audit includes examining, on a test basis, evidence
supporting  the amounts and  disclosures in the financial  statements.  An audit
also includes assessing the accounting principles used and significant estimates
made by  management,  as well as  evaluating  the  overall  financial  statement
presentation.  We  believe  that our audit  provide a  reasonable  basis for our
opinion.

In our opinion,  these  financial  statements  present  fairly,  in all material
respects,  the  financial  position  of the  Company as at 31 March 2006 and the
results  of its  operations,  its cash flows and its  changes  in  stockholders'
deficiency  for the  year  then  ended in  accordance  with  Canadian  generally
accepted accounting principles.


Vancouver, British Columbia, Canada
                                                           Chartered Accountants
30 August 2006

Comments by Independent  Registered  Chartered  Accountants for United States of
America Readers on Canada - United States of America Reporting Differences

The standards of the Public Company Accounting Oversight Board (United States of
America)  requires  the  addition of an  explanatory  paragraph  (following  the
opinion paragraph) when the financial  statements are affected by conditions and
events that cast  substantial  doubt on the  Company's  ability to continue as a
going concern,  such as those  described in Note 1 to the financial  statements.
Although we conducted  our audits in  accordance  with both  Canadian  generally
accepted auditing  standards and the standards of the Public Company  Accounting
Oversight Board (United States of America),  our report to the  Stockholders and
Board of Directors  dated 26 June 2006 is expressed in accordance  with Canadian
reporting  standards,  which do not permit a reference  to such  conditions  and
events in the  report  when  these are  adequately  disclosed  in the  financial
statements.


Vancouver, British Columbia, Canada                        Chartered Accountants
30 August 2006

                                      F-1
<PAGE>



Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Balance Sheets
(Expressed in Canadian Dollars)
As at 31 March
--------------------------------------------------------------------------------
                                                             2006          2005
                                                                $             $
 Assets

 Current
 Cash and cash equivalents                                    165          --
Amounts receivable (Note 3)                                  --          10,155
                                                       ----------    ----------
                                                              165        10,155
                                                       ==========    ==========

Liabilities

Current
Accounts payable and accrued liabilities (Note 5)         154,192       216,861
Due to related parties (Note 6)                           366,854       242,256
                                                       ----------    ----------
                                                          521,046       459,117
                                                       ----------    ----------
Stockholders' deficiency
Capital stock (Note 8)
Authorized
  Unlimited common shares without par value
Issued and outstanding
    2006 - 116,195,645 common shares
    2005 - 16,195,645 common shares                     4,990,523     4,980,523
Additional paid-in capital                                 30,000          --
Deficit                                                (5,541,404)   (5,429,485)
                                                       ----------    ----------
                                                         (520,881)     (448,962)
                                                       ----------    ----------
                                                              165        10,155
                                                       ==========    ==========



Nature  and  Continuance  of  Operations  (Note  1),  Commitment  (Note  11) and
Subsequent Events (Note 12)

On behalf of the Board:

                        Director
-----------------------
Don Perks

   The accompanying notes are an integral part of these financial statements.

                                      F-2

<PAGE>
<TABLE>
<CAPTION>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Statements of Operations and Deficit
(Expressed in Canadian Dollars)
For the years ended 31 March
----------------------------------------------------------------------------------------
                                                      2006           2005           2004
                                                         $              $              $
<S>                                            <C>            <C>            <C>

Expenses
General and administrative (see Schedule 1)        (81,366)       (98,728)      (299,548)
                                               -----------    -----------    -----------

Net loss before other items                         (81,366)       (98,728)      (299,548)
Other items
Foreign exchange loss                                 (553)          --             --
Forgiveness of debt                                   --          144,728           --
Gain from the sale of mineral rights                  --             --          149,999
Legal settlement                                      --          165,000           --
Write-off of loan receivable (Note 4)              (30,000)          --             --
Write-off of equipment                                --           (1,623)          --
Write-off of loan receivable                          --         (150,000)          --
                                               -----------    -----------    -----------

Net income (loss) for the year                    (111,919)        59,377       (149,549)
Deficit, beginning of year                      (5,429,485)    (5,488,862)    (5,339,313)
                                               -----------    -----------    -----------
Deficit, end of year                            (5,541,404)    (5,429,485)    (5,488,862)
                                               ===========    ===========    ===========
Basic and diluted earnings (loss) per share          (0.01)          0.01          (0.01)
                                               ===========    ===========    ===========
Weighed average number of common shares
outstanding                                     94,825,781     16,195,645     14,995,642
                                               ===========    ===========    ===========
</TABLE>













   The accompanying notes are an integral part of these financial statements.

                                      F-3
<PAGE>
<TABLE>
<CAPTION>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Statements of Cash Flows
(Expressed in Canadian Dollars)
 For the years ended 31 March
---------------------------------------------------------------------------------------------
                                                                 2006        2005        2004
                                                                    $           $           $
<S>                                                          <C>           <C>       <C>
Cash flows from operating activities
Net income (loss) for the year                               (111,919)     59,377    (149,549)
  Adjustments to reconcile loss to net cash used by
  operating activities
    Amortization                                                 --         1,623         132
    Common shares issued as repayment of accounts
    payable                                                      --          --        75,000
    Write-off of loan receivable (Notes 4 and 10)              30,000        --          --
    Contributions to capital by related party -
    expenses (Note 7)                                          30,000        --          --
    Gain on sale of mineral rights                               --          --      (149,999)
                                                             --------    --------    --------
                                                                          (51,919)   (224,416)
                                                                                       61,000
Changes in operating assets and liabilities
  Decrease (increase) in amounts receivable (Note 3)           10,155      (4,998)     (3,470)
  Increase (decrease) in accounts payable (Notes 5 and 10)    (26,428)    (82,123)    162,632
                                                             --------    --------    --------
                                                              (68,192)    (26,121)    (65,254)
                                                             --------    --------    --------
Cash flows from financing activities                           10,000        --          --
Common shares issued for cash (Note 8)
(Increase) in loan receivable (Notes 4 and 10)                (30,000)       --          --
Increase (decrease) in loan payable                              --      (337,745)    212,745
Increase (decrease) in due to related party (Notes 7
and 10)                                                        88,357     361,286    (145,223)
                                                             --------    --------    --------
                                                               68,357      23,541      67,522
                                                             --------    --------    --------
Increase (decrease) in cash and cash equivalents               (2,580)
                                                                              165       2,268
Cash and cash equivalents, beginning of year                     --         2,580         312
                                                             --------    --------    --------
Cash and cash equivalents, end of year                            165        --         2,580
                                                             ========    ========    ========
</TABLE>


Supplemental Disclosures with Respect to Cash Flows (Note 10)






   The accompanying notes are an integral part of these financial statements.

                                      F-4

<PAGE>
<TABLE>
<CAPTION>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Statements of Changes in Stockholders' Deficiency
(Expressed in Canadian Dollars)
------------------------------------------------------------------------------------------------------------
                                                                 Additional
                                  Number of                         paid-in                    Stockholders'
                              shares issued   Share capital         capital         Deficit       deficiency
                                                          $               $               $                $
<S>                           <C>             <C>             <C>             <C>              <C>

Balance at 31 March 2004         16,195,642       4,980,523            --        (5,488,862)        (508,339)
   Net income for the year             --              --              --            59,377           59,377
                              -------------   -------------   -------------   -------------    -------------
Balance at 31 March 2005         16,195,645       4,980,523            --        (5,429,485)        (448,962)

   Shares issued in escrow
   (Note 8)                     100,000,000          10,000            --              --             10,000
   Contributions to capital
   by related party -
   expenses (Note 7)                   --              --            30,000            --             30,000
   Net loss for the year               --              --              --          (111,919)        (111,919)
                              -------------   -------------   -------------   -------------    -------------
Balance at 31 March 2006        116,195,645       4,990,523          30,000      (5,541,404)        (520,881)
                              =============   =============   =============   =============    =============
</TABLE>




























   The accompanying notes are an integral part of these financial statements.

                                      F-5
<PAGE>




Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Schedule 1 - General and Administrative Expenses
(Expressed in Canadian Dollars)
For the years ended 31 March
--------------------------------------------------------------------------------
                                               2006          2005          2004
                                                  $             $             $
                                         ----------    ----------    ----------
Amortization                                   --            --             132
Bank charges and interest                     2,200           140         5,347
Consulting                                     --            --          59,664
Investor relations                             --             800         2,213
Legal and accounting fees                    32,364        86,433       135,478
Management fees (Note 7)                     24,000          --            --
Office and administration                     1,340          --          14,402
Rent (Note 7)                                 6,000          --            --
Salaries and benefits                          --            --          10,500
Transfer agent and filing fees               11,689        10,344        35,282
Travel                                        3,773          --          25,816
Trust and filing fees                          --           1,011        10,714
                                         ----------    ----------    ----------
                                            (81,366)      (98,728)     (299,548)
                                         ==========    ==========    ==========



















   The accompanying notes are an integral part of these financial statements.

                                      F-6
<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
For the years ended 31 March
--------------------------------------------------------------------------------


1.   Nature and Continuance of Operations

     Global  Immune  Technologies  Inc.  (the  "Company")  (formerly  Secureview
     Systems Inc.) was  incorporated  on 18 September 1985 in British  Columbia,
     Canada.  The Company was  organized  for the purpose of  exploring  mineral
     properties.

     The  Company's  financial  statements  as at 31 March 2006 and for the year
     then ended have been prepared on a going concern basis,  which contemplates
     the realization of assets and the settlement of liabilities and commitments
     in the normal  course of  business.  The Company has a loss of $111,919 for
     the year  ended 31 March  2006  (2005 - income of  $59,377,  2004 - loss of
     $149,549) and has a working capital deficiency of $520,881 at 31 March 2006
     (2005 - $448,962).

     Management  cannot  provide  assurance  that the  Company  will  ultimately
     achieve  profitable  operations  or  become  cash flow  positive,  or raise
     additional  debt  and/or  equity  capital.  Management  believes  that  the
     Company's  capital  resources should be adequate to continue  operating and
     maintaining  its business  strategy  during the fiscal year ending 31 March
     2007.  However, if the Company is unable to raise additional capital in the
     near future,  due to the Company's  liquidity  problems  management expects
     that the Company will need to curtail  operations,  liquidate assets,  seek
     additional  capital on less  favorable  terms and/or pursue other  remedial
     measures. These financial statements do not include any adjustments related
     to the  recoverability  and  classification  of assets or the  amounts  and
     classification of liabilities that might be necessary should the Company be
     unable to continue as a going concern.

     Management is currently  attempting to implement its business  plan, and is
     seeking additional sources of equity or debt financing, however there is no
     assurance  these  activities will be successful.  Accordingly,  the Company
     must  rely  on  its  president  to  perform  essential   functions  without
     compensation  until a business  operation can be  commenced.  These factors
     raise  substantial  doubt about the ability of the Company to continue as a
     going concern. The financial statements do not include any adjustments that
     might  result  from  the  outcome  of  this  uncertainty.

2.   Significant Accounting Policies

     The following is a summary of significant  accounting  policies used in the
     preparation of these financial statements.

     Basis of presentation

     The  accounting  policies of the Company are in  accordance  with  Canadian
     generally accepted  accounting  principles  ("Canadian GAAP") applicable to
     development stage enterprises, and are expressed in Canadian dollars. These
     policies  conform,  in all material  respects,  with accounting  principles
     generally  accepted in the United States of America ("United States GAAP"),
     except  as  described  in  Note  13.  Outlined  below  are  those  policies
     considered particularly significant.





                                      F-7
<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
For the years ended 31 March
--------------------------------------------------------------------------------


     Cash and cash equivalents

     Cash and cash equivalents  include highly liquid  investments with original
     maturities of three months or less.

     Financial instruments

     The carrying value of cash, accounts payable and accrued  liabilities,  and
     due to related parties  approximates  their fair value because of the short
     maturity of these  instruments.  Unless otherwise noted, it is management's
     opinion that the Company is not exposed to significant  interest,  currency
     or credit risk arising from these financial instruments.

     Derivative financial instruments

     The  Company has not, to the date of these  financial  statements,  entered
     into  derivative  instruments  to offset  the  impact of  foreign  currency
     fluctuations.

     Income taxes

     Future income tax assets and liabilities are determined  based on temporary
     differences  between  the  accounting  and the tax bases of the  assets and
     liabilities  and for loss carry  forwards,  and are measured  using the tax
     rates  expected  to apply  when  these  differences  reverse.  A  valuation
     allowance is recorded against any future income tax asset if it is not more
     likely than not that the asset will be realized.  As at 31 March 2006,  the
     Company's  net future  income tax  assets are fully  offset by a  valuation
     allowance.

     Basic and diluted net loss per share

     Basic loss per share is calculated  based on the weighted average number of
     shares outstanding during the period. The treasury stock method is used for
     determining   the  dilutive  effect  of  options  and  warrants  issued  in
     calculating  diluted  earnings per share.  Under this method,  the dilutive
     effect  on loss per share is  recognized  on the use of the  proceeds  that
     could be  obtained  upon the  exercise  of  options,  warrants  and similar
     instruments.  It assumes that the proceeds would be used to purchase common
     shares  at the  average  market  price  during  the  year.  For  the  years
     presented, this calculation proved to be anti-dilutive.

     Foreign currency translation

     The Company's  functional  and reporting  currency is in Canadian  dollars.
     Monetary  assets and  liabilities  denominated  in foreign  currencies  are
     translated  into Canadian  dollars at the rate of exchange in effect at the
     balance sheet date. Non-monetary assets and liabilities are translated into
     Canadian  dollars  at  their  applicable  historical  rates.  Revenues  and
     expenses are translated at rates  prevailing at the date of the transaction
     except for amortization,  which is translated at historical rates. Exchange
     gains and losses from the translation of foreign  currencies are recognized
     in the period in which they occur.


                                      F-8
<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
For the years ended 31 March
--------------------------------------------------------------------------------


     Use of estimates

     The  preparation of financial  statements in conformity  with Canadian GAAP
     requires  management  to make  estimates  and  assumptions  that affect the
     amounts of assets and liabilities and disclosures of contingent  assets and
     liabilities  at the  date of the  financial  statements  and  the  reported
     amounts of revenues and expenditures  during the reporting  period.  Actual
     results could differ from these estimates.

     Comparative figures

     Certain  comparative  figures have been  adjusted to conform to the current
     period's presentation.

3.   Amounts  Receivable

     Amounts  receivable  are  non-interesting   bearing,   unsecured  and  have
     settlement dates within one year.


                                                           As at 31     As at 31
                                                         March 2006   March 2005
                                                                  $            $


      Goods and Services Tax receivable                        --         10,155
                                                         ==========   ==========

4.   Loan Receivable


     During  the year ended 31 March  2006,  the  Company  loaned  $30,000  cash
     pursuant  to an  agreement  dated  23  September  2005  to  Global  Lottery
     Corporation,  a Nevada  corporation.  The terms of the agreement state that
     the  Company  shall have the option to convert  this  promissory  note into
     shares of common stock of Global Lottery  Corporation on the basis of $0.10
     per share.  Management  believes collection is doubtful and the balance has
     been offset by a full valuation  allowance as at 31 March 2006.

5.   Accounts Payable and Accrued Liabilities

     Accounts  payable  and  accrued   liabilities  are  non-interest   bearing,
     unsecured and have settlement dates within one year.


                                      F-9
<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
For the years ended 31 March
--------------------------------------------------------------------------------


6.   Due to Related Parties

     As at 31 March 2006,  the amount due to related  party  consists of $54,539
     (2005 -  $36,170)  payable to a  shareholder  and  officer-director  of the
     Company.

     As at 31 March 2006,  the amount due to related  party  consists of $44,987
     (2005 - $Nil) payable to a shareholder of the Company.

     As at 31 March  2006,  the amount due to related  party  includes  $267,328
     (2005 - $206,086) payable to a shareholder of the Company.

     Amounts due to related parties are non-interest bearing, unsecured and have
     no fixed terms of repayment.

7.   Related Party Transactions

     During the year ended 31 March 2006, the Company entered into the following
     transactions with related parties:

     i.   During the year  ended 31 March  2006,  officers-directors,  and their
          controlled entities, have made contributions to capital for management
          fees and rent in the amount of $24,000 (2005 - $Nil,  2004 - $Nil) and
          $6,000 (2005 - $Nil, 2004 - $Nil) respectively (Note 10).

     ii.  An amount of $12,835  was paid by a director  and  shareholder  of the
          Company to settle outstanding accounts payable balances.

     iii. Directors and companies  with common  directors  received $Nil (2005 -
          $Nil, 2004 - $30,000) for consulting,  administrative,  rent,  office,
          shareholder relations, and management services.

     The  amounts  charged to the Company for the  services  provided  have been
     determined by negotiation among the Company and the related parties, and in
     certain cases, are covered by signed agreements.  It is the position of the
     management of the Company that these transactions were in the normal course
     of operations and were measured at the exchange value which represented the
     amount of  consideration  established and agreed to by the related parties.

8.   Capital Stock

     Authorized

     In May  2005,  the  Company  altered  its  authorized  capital  stock  from
     100,000,000  common shares to an unlimited  number of common shares without
     par value.


                                      F-10
<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
For the years ended 31 March
--------------------------------------------------------------------------------

     Issued and outstanding

     The total issued and outstanding capital stock is 116,195,645 common shares
     without a par value.

     During the year ended 31 March 2006, the Company  proceeded with a proposed
     acquisition  of the rights to the drug  Trioxolane.  Under the terms of the
     transaction,  the Company issued  100,000,000 common shares in trust, which
     were  held in escrow  subject  to  completion  of the  acquisition.  As the
     transaction was not completed,  the common shares were returned to treasury
     and the Company is in the process of canceling the certificates.

     Share purchase warrants

     The following share purchase warrants were outstanding at 31 March 2006:

                                                                       Remaining
                                                     Number     contractual life
                            Exercise price      of warrants              (years)
                                         $

     Warrants (Note 11)               0.03        2,500,000                  1.7
                                                -----------
                                                  2,500,000
                                                ===========

     A summary of outstanding share purchase warrants is as follows:

                                                         Number of      Weighted
                                                             share       average
                                                          purchase      exercise
                                                          warrants         price
                                                                               $


     Outstanding and exercisable at 1 April 2005         2,500,000          0.03
     Granted                                                  --
     Exercised                                                --
     Forfeited                                                --
                                                         ----------   ----------
     Outstanding and exercisable at 31 March 2006         2,500,000         0.03

     Stock options


     Under the  Company's  stock option plan,  the Company may grant  options to
     employees,  officers,  and  directors  for the purchase of its common stock
     from  treasury.  The  aggregate  number of shares so reserved  for issuance
     shall  not  exceed  10% of the  issued  and  outstanding  shares,  and  the


                                      F-11

<PAGE>
<TABLE>
<CAPTION>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
For the years ended 31 March
--------------------------------------------------------------------------------

     aggregate  number of shares so reserved for issuance to any one  individual
     shall not exceed 5% of the issued and outstanding  shares.  Under the plan,
     the options are exercisable  upon issuance and an option's  maximum term is
     five years.

                                                                2006       2005
                                                                   $          $

     Outstanding and exercisable at 1 April 2005                --      427,729
     Granted                                                    --         --
     Exercised                                                  --         --
     Forfeited                                                  --         --
     Cancelled                                                  --     (427,729)
                                                            --------   --------
     Outstanding and exercisable at 31 March 2006               --         --
                                                            ========   ========


9.   Income Taxes

     Provision for income taxes

     The  provision  for (recovery of) income taxes differs from the amount that
     would have resulted by applying  Canadian federal and provincial  statutory
     tax rates of 34.1%  (2005 - 35.6%,  2004 - 35.6%) to net income  (loss) for
     the years as follows:

                                                          2006        2005        2004
                                                             $           $           $
     <S>                                              <C>           <C>       <C>

     Net income (loss) before income taxes            (111,919)     59,377    (149,549)
                                                      --------    --------    --------
     Income tax recovery at statutory rates             38,187     (20,259)     53,269
     Adjustments to benefits resulting from:
      Amortization                                        --          --           (45)
      Contributions to capital by related party        (10,236)
      (Unrecognized) benefits of non-capital losses    (27,951)     20,259     (53,224)
                                                      --------    --------    --------
     Future income tax recovery                           --          --          --
                                                      ========    ========    ========
     </TABLE>











                                      F-12
<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
For the years ended 31 March
--------------------------------------------------------------------------------


     Future tax balances

     The tax effects of temporary  differences  that give rise to future  income
     tax assets and liabilities are as follows:

                                                              2006         2005
                                                                 $            $

     Future tax assets:
       Non-capital loss carryforwards                      519,310      676,400
       Less: valuation allowance                          (519,310)    (676,400)
                                                         ---------    ---------
     Net future tax assets                                    --           --
                                                         =========    =========


     As at 31 March  2006,  the  Company has  accumulated  operating  losses for
     income  tax  purposes  of  approximately  $1,462,141  which may be  carried
     forward to reduce taxable income of future years. The potential tax benefit
     of these losses has not been reflected in the financial statements as it is
     more likely  than not that these  losses  will not be  utilized.  They will
     expire at various dates to 31 March 2016. The potential  income tax benefit
     of these losses has been offset by a full valuation allowance.

10.  Supplemental Disclosures with Respect to Cash Flows

                                                         2006     2005     2004
                                                            $        $        $
     Cash paid during the year for interest               --       --       --
     Cash paid during the year for income taxes           --       --       --


     During the year ended 31 March 2006, the Company  provided a full valuation
     allowance for a loan receivable of $30,000 (Note 4).

     During the year ended 31 March 2006, an officer,  director and  shareholder
     of the Company made  contributions  to capital for management fees and rent
     of $24,000 (2005 - $Nil) and $6,000 (2005 - $Nil) respectively (Note 7).

     During the year ended 31 March 2006, a company  controlled by a shareholder
     of the Company assumed accounts payable of $36,241. 11. Commitment

     As at 31 March  2006,  the  Company  had  outstanding  warrants to purchase
     2,500,000  shares of the  Company's  common  shares at a price of $0.03 per
     share. The warrants became  exercisable in 2004 and expire at various dates
     through  2007.  At 31 March  2006,  2,500,000  shares of common  stock were
     reserved for that purpose.


<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
For the years ended 31 March
--------------------------------------------------------------------------------


12.  Subsequent Events

     Subsequent to 31 March 2006, the following events occurred:

     i.   Effective 2 May 2006,  the Company  changed its name to Global  Immune
          Technologies Inc. from Secureview Systems Inc.

     ii.  The  Company  was  voluntarily  dissolved  in the  province of British
          Columbia and obtained articles of continuance in the State of Wyoming.

     iii. On 19 July  2006,  the  Company  entered  into a  securities  exchange
          agreement  (the   "Agreement")   with  MediPri   Limited   ("MedPri"),
          Primedical  International  Ltd. ("PML"),  and Medical Monitors Limited
          ("MML").  Under the  Agreement,  the  Company  shall  issue to PML the
          following securities;


          a)   A total of 74,000,000 common shares of the Company,

          b)   A total of 7,400,000  share purchase  warrants where each warrant
               represents  the right to purchase one common share of the Company
               at a price of $0.5 0USD for a period of five  years from the date
               of the Agreement.

          c)   A  promissory   note  in  the  amount  of   $10,000,000   payable
               automatically  and without demand on the third anniversary of the
               date of the Agreement. This promissory note is to be non-interest
               bearing and convertible  into common shares of the Company at the
               holder's  option  at any time  prior to the  maturity  date,  the
               conversion  amount  is to  be at a  price  equal  to  eighty-five
               percent of the  average  closing  price of the  Company's  common
               shares over the five business days immediately preceding the date
               of the conversion. At no time shall such conversion price be less
               than $0.40USD or greater than $1 .00USD.

          d)   A promissory note issued to MML in consideration for intellectual
               property,  bearing  no  interest,  in  the  principle  amount  of
               $4,000,000USD,  payable  automatically  and without demand on the
               first anniversary of the date of this agreement.  Such note shall
               be convertible  into common shares of the Company at the holder's
               option at any time prior to the maturity date, such conversion to
               be at a price equal to eighty-five percent of the average closing
               price  of  the  Company's  common  shares  over  the  immediately
               preceding  five business  days. At no time shall such  conversion
               price be less than $0.40USD or greater than $ 1.00USD.

     In exchange for the issuance by the Company to PML of the Company's shares,
     warrants,  and promissory notes, PML shall assign and convey to the Company
     all of its interest in  58,302,000  shares of common stock of MedPri.  Such
     shares are to constitute all of the outstanding capital stock of MedPri.


                                      F-14
<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
For the years ended 31 March
--------------------------------------------------------------------------------


13.  Reconciliation of Canadian and United States Generally Accepted  Accounting
     Principles

     These  financial  statements have been prepared in accordance with Canadian
     GAAP. Except as set out below,  these financial  statements also comply, in
     all material respects, with United States GAAP.

     Statement of cash flow differences

     Under  United  States  GAAP,  separate  subtotals  within  cash  flow  from
     operating activities are not presented.

     i.   Comprehensive income

          Statement  of  Financial   Accounting   Standards  ("SFAS")  No.  130,
          "Reporting  Comprehensive  Income",   establishes  standards  for  the
          reporting  and  display of  comprehensive  income  and its  components
          (revenues,  expenses,  gains, and losses).  SFAS No. 130 requires that
          all  items  that  are  required  to  be  recognized  under  accounting
          standards as  components  of  comprehensive  income be reported in the
          financial statements for the Company. There are no differences between
          net loss and  comprehensive  loss for each of the years ended 31 March
          2006, 2005 and 2004.

     ii.  Accounting  for  impairment  of long-lived  assets and for  long-lived
          assets to be disposed of

          For United States reporting purposes, the Company has adopted SFAS No.
          144, "Accounting for the Impairment or Disposal of Long-Lived Assets".
          In the event that facts and  circumstances  indicate that the carrying
          amount of an asset may not be  recoverable  and an  estimate of future
          and  undiscounted  cash flows is less than the carrying  amount of the
          asset, an impairment loss will be recognized.

     iii. Income taxes

          Under United States GAAP,  deferred  income tax assets and liabilities
          are  revalued  for all enacted  changes in tax rates.  Under  Canadian
          GAAP,  deferred income tax assets and liabilities are revalued for all
          enacted or substantially enacted changes in tax rates.

     iv.  Recent pronouncements

          Management  does not believe  that any  recently  issued,  but not yet
          effective,  accounting  standards  if currently  adopted  would have a
          material effect on the accompanying financial statements.

     v.   Loss per share

          Under  Canadian  GAAP,  shares  held in  escrow  are  included  in the
          calculation of loss per share.  Under United States GAAP,  shares held
          in escrow  are  excluded  from the  weighted-average  number of shares
          outstanding until such shares are released for trading.


                                      F-15
<PAGE>
<TABLE>
<CAPTION>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
For the years ended 31 March
--------------------------------------------------------------------------------


     The following is a reconciliation of the numerators and denominators of the
     basic and diluted loss per share calculations:

                                                             For the        For the       For the
                                                          year ended     year ended    year ended
                                                            31 March       31 March      31 March
                                                                2006           2005          2004
                                                                   $              $             $
     <S>                                                 <C>            <C>            <C>

     Numerator: Net income (loss) for the year under
     U.S. GAAP                                              (111,919)        59,377      (149,549)
     Denominator: Weighted average number of shares
     under Canadian GAAP                                  94,825,781     16,195,645    14,995,642
     Adjustment required under U.S. GAAP to exclude
     stock held in escrow (Note 8)                       (78,630,136)          --            --
                                                         -----------    -----------   -----------
     Weighted average number of shares under U.S.
     GAAP                                                 16,195,645     16,195,645    14,995,642
                                                         ===========    ===========   ===========
     Basic and diluted earnings (loss) per share under
     U.S. GAAP                                                 (0.01)          0.01         (0.01)
                                                         ===========    ===========   ===========
     </TABLE>



















                                      F-16